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Hepatocellular carcinoma (HCC) is the most common form of liver cancer and has a high 
mortality rate. Heat shock protein 90 (Hsp90) has been identified as a potential therapeutic 
target for HCC as this molecular chaperone was found to facilitate the folding of oncoproteins. 
Two naturally occurring Hsp90 inhibitors, geldanamycin and radicicol, are known to antagonize 
the functions of Hsp90. Previous studies had demonstrated that derivatives of geldanamycin such 
as 17-allyl-17-demethoxygeldanamycin (17-AAG), were able to reduce cell growth and induce 
apoptosis in HCC cells. However, geldanamycin and its derivatives possess a quinone moiety that 
is likely to induce cellular cytotoxicity. As a result, it remains questionable whether the observed 
effects in the HCC cells were attributed to the inhibition of Hsp90’s functionality or the quinone 
moiety. Hence, this project was undertaken to investigate the cellular effects of Hsp90 inhibition 
through the use of radicicol, which does not possess the quinone moiety. In addition, given that 
the downstream molecular effects of Hsp90 inhibition in HCC remain unclear, this study also 
aimed to uncover molecules that were deregulated in HCC cells after treatment with the Hsp90 
inhibitor, 17-AAG.  
Firstly, 17-AAG and radicicol were independently shown in this study to reduce cellular 
growth and increase apoptosis in HCC cells in vitro. The live cell imaging revealed that both the 
Hsp90 inhibitors induced cell cycle arrest at the mitotic stage of the cell cycle. Further 
investigation using fluorometric assay found that treatment with 17-AAG activated the protease 
activity of caspase 9, indicating that 17-AAG induced cell death via the intrinsic pathway. 
Furthermore, the wound-healing assay revealed that Hsp90 inhibitor treatment decreased HCC 
cell motility. In addition, Hsp90 inhibitors were found to be effective in targeting HCC cells but 
not on the non-tumourigenic NehepLXTH cells. Collectively, these results have highlighted the 
importance of Hsp90 in crucial cellular processes such as cell cycle, cell death and cell motility, 
and demonstrated the selectivity of Hsp90 inhibitors in targeting the tumour cells.  
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Following which, antibody array and gene expression microarray were used to uncover 
molecules that were deregulated by 17-AAG, at both the protein and transcript levels. The 
identified molecules were subsequently analyzed using Ingenuity Pathway Analysis (IPA) 
programme. The analysis identified several key cellular molecules such as epidermal growth 
factor receptor (EGFR), p21/WAF1 (CDKN1A) and B-cell lymphoma 2 (Bcl-2) that could have 
played a role in 17-AAG-induced cell cycle arrest and apoptosis. In addition, the extracellular-
signal-regulated kinases/mitogen-activated protein kinase (ERK/MAPK) and phosphatidylinositol 
3-kinase/Akt/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathways which are 
important in the HCC pathogenesis were also found to be altered after treatment with 17-AAG. 
These findings suggested that inhibition of Hsp90 could potentially target multiple signaling 
pathways of importance to HCC pathogenesis, and hence presents an attractive therapeutic 
strategy for HCC treatment.  
Interestingly, genes involved in the nuclear respiratory factor 1 (NRF-1) response to 
oxidative stress pathway was found to be deregulated upon exposure to 17-AAG. One of these 
deregulated genes was superoxide dismutase 2 (SOD2). Western blot analysis subsequently 
verified that the SOD2 protein was upregulated in Huh-7 cells after treatment with 17-AAG. This 
increased SOD2 level may consequently promote the tolerance of cells against oxidative stress. 
Hence, to verify this postulation, HCC cells were pre-treated with 17-AAG and the cells were 
found to exhibit greater tolerance towards oxidative stress-induced apoptosis. This observation 
highlighted the potential undesirable effects that could arise from the use of Hsp90 inhibitors. 
In summary, this study had demonstrated the cellular effects of Hsp90 inhibition in HCC 
cells using two chemically distinct inhibitors. It also uncovered the downstream molecular effects 
of Hsp90 inhibition in HCC cells and consequently, its impact on various biochemical pathways 
that could have led to the observed cellular effects induced by Hsp90 inhibitors. These findings 
may be valuable in the exploitation of Hsp90 as a therapeutic application for treating HCC. 
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Chapter 1: Introduction 
 
1.1 Hepatocellular Carcinoma: A Global Concern  
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for 
90% of all primary hepatic malignancies. Globally, it is the fifth most common cancer and the third 
leading cause of cancer deaths (McGlynn and London, 2011). The disease has a poor prognosis of 
less than 3% five-year survival rate. Every year, there are an estimated 500,000 cases of death 
related to HCC. The disease is of concern in Singapore, as the incidence rate of HCC was found to be 
higher in Southeast Asia as compared to United States and Western Europe (Yuen et al., 2009). With 
the number of HCC cases expected to rise in the coming years (Venook et al., 2010),  greater urgency 
is required to combat this health problem.  
The poor survival outcome of HCC patients is primarily attributed to two reasons, which are 
1) unresponsiveness to treatment and 2) late symptom manifestation. Currently, there is no 
effective treatment for HCC patients. Conventional chemotherapeutic treatment remains an 
ineffective option with a low response rate of 5-10% (Farazi and DePinho, 2006). Surgical resection 
and liver transplantation are currently the most effective methods to treat the disease. However, 
these options are limited to a minority of patients with tumours that are small and localized (Olsen 
et al., 2010). Even so, patients who undergo the surgical procedures face a 56% chance of remission. 
In addition, the late manifestation of the disease symptoms denies the avenue of early therapeutic 
intervention. Currently, alpha-fetoprotein (AFP) is the only diagnostic biomarker available for HCC 
detection (Lim et al., 2002). Unfortunately, the use of AFP in early detection of HCC is limited. 
Furthermore, AFP remains to be an unreliable clinical criterion for determining the degree of 
malignancy. Hence, a more effective treatment and reliable diagnostic marker are needed in order 
to improve the survival outcome of HCC patients. 
Chapter 1 Introduction 
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1.2 Hsp90 is an Important Molecular Chaperone in Eukaryotes 
Hsp90 is the most abundant molecular chaperone in eukaryotic cells, constituting 
approximately 1–2% of the total cytoplasmic proteins (Borkovich et al., 1989). It functions to prevent 
the aggregation of proteins, and facilitate protein folding and assembly of protein complexes. Unlike 
other chaperones, Hsp90 is primarily involved in the late stages of the protein folding process where 
proteins are near their maturation state (Buchner, 1999). This is where Hsp90 induces further 
structural changes in these proteins, allowing them to attain their final functional conformation.  
Thus far, Hsp90 has been implicated in the folding and activation of approximately 200 
proteins, which are known as Hsp90 client proteins (Pearl and Prodromou, 2006). While there is no 
commonality in the function of these client proteins, a striking feature of this list of proteins is the 
high proportion of conformationally flexible proteins such as kinases, hormone receptors and 
transcription factors (Young et al., 2001). More importantly, many of them are key regulatory 
elements in cell cycle control, cell proliferation and apoptosis. Their functionalities are dependent on 
the chaperone activity of Hsp90 to promote their maturation and stability (Richter and Buchner, 
2001). Disruption of this process would result in aberrant proteins that are consequently 
ubiquitinated for proteosomal-mediated degradation. With the fate of these proteins determined by 
Hsp90, the chaperone is thus able to indirectly influence numerous cellular processes such as cell 
growth, differentiation and apoptosis. Not surprisingly, deletion of the Hsp90 gene was shown to be 
lethal to Saccharomyces cerevisiae (Borkovich et al., 1989), Drosophila melanogaster (van der 
Straten et al., 1997) and Caenorhabditis elegans (Birnby et al., 2000). Homozygous mutation of the 
constitutively expressed Hsp90β was found to impair embryonic development of the mice (Voss et 
al., 2000). In addition, heterozygous deletions of Hsp90 in D. melanogaster had resulted in 
abnormality in the progeny phenotype (Queitsch et al., 2002; Rutherford and Lindquist, 1998). These 
findings demonstrated that Hsp90 is an essential molecular chaperone in the eukaryotes and has a 
Chapter 1 Introduction 
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role in cellular development. Given its importance for cellular development and survival, Hsp90 has 
been proposed as a candidate for therapeutic interventions in many diseases such as cancer and 
neurodegenerative disorder.   
1.3 Hsp90 is a Promising Molecular Target and Biomarker for Cancer Therapy 
Functioning at the node of many cellular processes, Hsp90 interacts and activates many 
regulatory and signaling proteins. Among these, a notable number of Hsp90 client proteins are well-
characterized oncoproteins such as p53, Raf proteins and Akt. Therefore, it is not coincidental that 
Hsp90 has a major role in cancer development. The role of Hsp90 in maintaining cancer phenotype 
was first documented through the use of a Hsp90 inhibitor, geldanamycin, where it was found to 
inhibit the growth and reduce the survival of cancer cells (Whitesell et al., 1994). Hsp90 was shown 
to be the specific target of geldanamycin and more importantly, its inhibition was found to disrupt 
and destabilize the formation of V-SRC oncoprotein. The destabilization of V-SRC proteins led to the 
reversion of the transformed phenotype. Subsequent studies also demonstrated that the commonly 
upregulated pro-oncogenic pathways such as the Akt-mediated survival-signaling and the Raf-MAPK 
growth pathway were likewise regulated by Hsp90. (Sato et al., 2000; Schulte et al., 1995). In 
addition, Hsp90 was shown to prevent apoptotic progression by indirectly activating NF-κB through 
receptor interacting protein (Lewis et al., 2000). Collectively, these evidence indicated that Hsp90 
plays a crucial role in cancer development and confers survival advantage to the cancer cells.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
Interestingly, overexpression of Hsp90 was observed in numerous cancers despite it being 
highly expressed in normal cells. Through immunochemical and immunoblot analyses, Hsp90 was 
found to be overexpressed at the protein level in both the solid and haematological tumours. For 
example, in the breast cancer, the intensities of immunostaining for Hsp90 in ductal and invasive 
carcinomas were 60% and 40% higher respectively when compared to normal cells (Diehl et al., 
2009). Furthermore, the expression of Hsp90 correlated with the prognosis of patients suffering 
Chapter 1 Introduction 
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from breast cancer and non-small cell lung cancer (Pick et al., 2007). This strongly suggests that 
cancer cells demand greater chaperone activity and the reliance on Hsp90 grows as the cancer 
develops. 
Notably, cancer cells were reportedly more sensitive to Hsp90 inhibitor, 17-AAG, than non-
transformed cells which are advantageous for targeting a ubiquitous protein (Diehl et al., 2009; 
Kamal et al., 2003). Hsp90 in tumour cells was reported to have a 100-fold higher binding affinity for 
17-AGG, as compared to Hsp90 in wild type cells (Kamal et al., 2003). Further investigations using co-
immunoprecipitation and ATPase activity assays had shown that a higher proportion of Hsp90 in 
tumour cells were engaged in multi-chaperones complexes and displayed a higher ATPase activity. In 
contrast, Hsp90 from wild-type cells was generally shown to be in an inactive and uncomplexed 
state. These results unveiled the molecular basis of the tumour selectivity of Hsp90 inhibitors.  
As the evidence showed, the protein repertoire in cancer cells was more dependent on 
Hsp90 as compared to non-transformed cells which leads to the postulation that inhibition of Hsp90 
would simultaneously regress multiple interconnected signaling pathways (Bagatell and Whitesell, 
2004) and impair the characteristic capabilities of cancer. Currently, there are at least 13 Hsp90 
inhibitors undergoing clinical evaluation in 23 active oncology trials (Kim et al., 2009). Despite 
recognizing the therapeutic potential of inhibiting Hsp90, limited studies had been carried out on the 
use of Hsp90 inhibitors in HCC. The mechanistic basis on the inhibition of Hsp90 at the molecular 
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1.4 Cellular and Molecular Responses of the Inhibition of Hsp90 in HCC Remain Poorly Understood 
While the role of Hsp90 has been extensively studied in a number of cancers such as lung, 
breast and prostate cancers, few studies had investigated the role of Hsp90 and the molecular 
responses to Hsp90 inhibitors in HCC. To date, there are three studies had showed that Hsp90 
protein level were elevated in HCC tumours (Lim et al., 2005; Lim et al., 2002; Sun et al., 2010). The 
protein expression of Hsp90 was found to correlate with poorer prognosis in HCC patients (Pascale 
et al., 2005). In addition, Hsp90 protein level was detected to be elevated in patient serum (Sun et 
al., 2010). This demonstrated the potential of Hsp90 as a biomarker. Although a larger sample size 
study on Hsp90 expression in HCC patients is necessary to further validate the prognostic value of 
Hsp90 in HCC, these findings have provided first-hand evidence on the valuable role of Hsp90 in 
HCC.  
At present, inhibition of Hsp90 using specific inhibitor was shown to inhibit cell proliferation 
through cell cycle arrest and inducing apoptosis in HCC. The abrogation of Hsp90’s activity was found 
to reduce the expression and activities of important oncogenic molecules that ranges from receptors 
(insulin-like growth factor receptor 1 and hepatocyte growth factor receptor) to kinases (protein 
kinase B, cyclin-dependent kinase 4 and Raf-1) (Breinig et al., 2009). However, other studies, 
attributed the observed cellular effects to the decrease in the protein levels of survivin, cyclin D1, 
nuclear Factor-KappaB (NFkB) and cyclin-dependent kinase 1 following Hsp90 inhibitor treatment 
(Leng et al., 2012; Watanabe et al., 2009). Given that Hsp90 is involved in multiple signaling 
pathways, it is likely that other proteins and specific pathways implicated by Hsp90 inhibition may 
not have been characterized yet. Hence, further investigation is required to understand the 
downstream molecular basis of Hsp90 inhibition in HCC. 
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1.5 Objectives of the Study 
After more than two decades of extensive studies on Hsp90, an increasing number of 
oncoproteins have been found to be chaperoned by Hsp90. Hsp90 inhibitors were able to arrest 
cancer progression in numerous xenograft models through the reduction of tumour size and growth 
rate as compared to vehicle treatment (Kelland et al., 1999; Williams et al., 2007). This includes liver 
cancer, skin cancer, prostate cancer, breast cancer and ovarian cancer. These evidence supported 
that Hsp90 inhibition would be efficacious towards many cancer cells. However, recent data 
reported by Hsp90 inhibitor clinical trials indicated otherwise (Kim et al., 2009). Results obtained 
from these trials suggested that the approach of examining certain key Hsp90 chaperoned 
oncogenes is inadequate for predicting either the clinical activity or the biological response of Hsp90 
inhibitors in the tumour tissue. Learning from these valuable lessons, the success in applying Hsp90-
targeted therapy will depend on gathering information with regards to cancer cell’s response 
towards Hsp90 inhibition at a global scale.  
The limited understanding of the roles of Hsp90 in HCC has posed a challenge in evaluating 
the therapeutic effects of inhibiting Hsp90 in this cancer disease. Since Hsp90 was suggested as a 
promising drug target in HCC, it thus necessitates further investigation of the response to Hsp90 
inhibition in HCC at both the cellular and molecular levels. The results obtained would not only 
provide insights into the cellular effects of Hsp90 inhibition but may also shed light on the molecular 
basis for these effects. In addition, potential new client proteins of Hsp90 and molecular pathways in 
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Aim 1. Investigation on the Cellular Effects of Hsp90 Inhibition in HCC  
 Although previous studies had demonstrated that Hsp90 inhibition reduced cell growth and 
induced apoptosis in HCC, the use of a single class of inhibitor was unable to differentiate “on-
target’’ effects (those which are a consequence of Hsp90 inhibition) from the “off-target” effects. 
Hence, this study seeks to re-examine the effects of Hsp90 inhibition through the use of the two 
chemically distinct Hsp90 inhibitors, radicicol and 17-AAG. In addition, characterization of the 
apoptosis profile induced by Hsp90 inhibitor would be pursued through analysing the activities of 
various caspases. With the high incidence of metastasis found in HCC, effects of Hsp90 inhibitors on 
cell mobility would also be examined. 
 
Aim 2.  Identification of the Molecular Effects of Hsp90 Inhibition in HCC 
Given the complexity in the nature of Hsp90 inhibition, a global approach is initiated in this 
study to provide a greater understanding on the biological basis of Hsp90 inhibition in HCC at the 
molecular level. The disruption of Hsp90’s functionality is not only likely to lead to protein 
expression changes but can also indirectly cause transcription aberration. Hence, both the protein 
array and genome-wide expression profiling were used to uncover molecules that were deregulated 
in HCC cells after treatment with the Hsp90 inhibitor, 17-AAG. This could potentially shed light on 
the molecular events that may lead to the aberration of cellular processes observed in cells treated 
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Chapter 2: Literature Review 
2.1 Molecular Chaperones in the Eukaryotes 
2.1.1 The Need for Chaperones to Maintain Protein Homeostasis 
Anfinsen’s classic in vitro experiments on the refolding of ribonuclease established the 
doctrine for polypeptide chain folding (Anfinsen, 1973). The amino acid sequence of a polypeptide 
withholds all the information that defines its tertiary structure. Under appropriate conditions, a 
denatured or newly synthesized protein can fold into its native conformation in the absence of any 
other proteins. However, these in vitro conditions were not observed in the in vivo cellular setting. 
The crowded cellular milieu and the unfavourable physicochemical conditions such as protein 
concentration, temperature, ionic strength and pH are detrimental to the stability of cellular 
proteins (Dezwaan and Freeman, 2008). Therefore, cells need to adopt the use of molecular 
chaperones to assist the folding of polypeptides. These molecular chaperones do so by increasing 
the efficiency of folding through reducing off-pathway aggregation and catalyzes the intra-
interaction within the proteins (Fink, 1999). In addition, molecular chaperone also participates in 
protein degradation and maintain proteins in an unfolded conformation for membrane 
translocation. Hence, molecular chaperone does not merely act as a catalyst for protein folding but 
also to promote proteins homeostasis within the cell. 
2.1.2 The Discovery of Heat Shock Proteins  
It was first reported in D. melanogaster that the synthesis of a set of proteins were found to 
be either induced or enhanced during stress conditions such as heat shock. This phenomenon was 
universally observed in organisms as diverse as bacteria, plant and human (Schlesinger, 1990). The 
proteins were later identified and termed as heat shock proteins (Hsp). Besides being stress-induced, 
there is a subset of Hsps, known as heat-shock cognate proteins (Hsc), which was found to be 
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constitutively expressed. In S. cerevisiae, there are two copies of Hsp90, namely Hsc82 and Hsp82, 
where the former is constitutively expressed and the latter being stress-inducible (Borkovich et al., 
1989). This indicates that the presence of Hsps is not only restricted to stress conditions but also 
extends to normal physiological conditions. 
Historically, Hsps were classified based on their approximate molecular weights (Table 2.1). 
However, with the improved understanding on the structures and functions of the different classes 
of Hsps, they are currently classified based on their sequence homology and functional domains. 
Within each of the Hsp protein family, the members are highly conserved in their structures and 
functions. Their abundance are generally indicative of their importance for the survival of the 
organism. Interestingly, most but not all of these Hsps function to facilitate the folding or assembly 
of another protein or protein complex without being a component of the final structure (Ellis and 
van der Vies, 1991; Ellis et al., 1989). 
2.1.3 Major Chaperones Involved in Protein Folding in Eukaryotes 
Major classes of Hsps include small Hsps (15-30 kDa), Hsp40, Hsp60, Hsp70, Hsp90, Hsp100 
and Hsp70-related Hsp110 (Table 2.1). While prokaryotes generally rely on Hsp60 (chaperonin 
GroEL) for protein folding, the eukaryotes possess a complex multi-chaperone machinery to facilitate 
protein folding in a more elaborated manner. The multi-step process primarily involves Hsp40, 
Hsp70 and Hsp90 chaperones and a set of regulators known as co-chaperones such as activator of 90 
kDa heat shock protein ATPase homolog 1 (Aha1) and prostaglandin E synthase 3 (p23). Hsp40 
facilitates the recruitment of client substrate and leads it to Hsp70 to initiate the de novo folding of 
nascent polypeptide chains. When the substrate is in its near-maturation state, Hsp90 would 
promote the final subtle changes and induce the substrate to its functional native state. As a rate-
limiting step, this final manoeuvre steered by Hsp90 is paramount to the “survival” of the substrate 
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which otherwise would be targeted for degradation (Schneider et al., 1996). As a result, Hsp90 is 
coined to be the guardian of the proteome. 
2.2 Heat Shock Protein 90 is an Essential Protein in Eukaryotes 
 Hsp90 is notably not a chaperone that is meant to facilitate the folding of every proteins in 
the eukaryotes. It functions to chaperone only a subset of proteins known as the Hsp90 client 
protein. Most proteins in this “exclusive pool” possess key influence over the cellular signaling and 
development pathways. They include transcription factors p53, STAT protein family and kinases such 
as B-RAF and cyclin dependent kinases (Taipale et al., 2010) (Figure 2.1). Genome-wide studies on 
the yeast suggested that 10% to 20% of total proteins can in one way or the other be affected by 
Hsp90’s activity (Breitkreutz et al., 2008; Zhao et al., 2005). The influence of Hsp90 should not be 
deemed to be restricted to the number of client proteins which it has direct interaction as Hsp90 
inhibition was also found to induce epigenetic changes and alteration of chromatin states in D. 
melanogaster (Tariq et al., 2009). Moreover, a novel concept brought forward by Rutherford and 
Lindquist extended the biological significance of Hsp90 to the morphological evolution of an 
organism (Queitsch et al., 2002; Rutherford and Lindquist, 1998). This was based on the observation 
that the reduction of Hsp90’s function resulted in various abnormal morphological developments in 
D. melanogaster. It was thus suggested that Hsp90 not only helped proteins to fold correctly but also 
buffered them phenotypically against mutations with deleterious effects. Taken together, Hsp90 can 
be considered to be one of the most important proteins in eukaryotes and compromising its function 
in the eukaryotes is likely lead to adverse consequences. 
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Table 2.1 – Classes of Heat Shock Proteins (Hsps) 
Classes of Hsp Eukaryote Prokaryote Description Function References 
10 kDa Heat 
Shock Protein 
Hsp10 GroES 
 Characteristic α-crystallin-domain at the C-terminus 
 Functions together with GroEL 
 Prevent protein aggregation in an 
ATP independent manner 
(Fink, 1999) 
20 - 30 kDa Heat 
Shock Protein 
Hsp27, HspB GroE 
 Characteristic α-crystallin-domain at the C-terminus  Prevent protein aggregation in an 
ATP independent manner 
(Fink, 1999) 
40 kDa Heat 
Shock Protein 
Hsp40 DnaJ 
 Consists of over 100 members and characterizes by 
the presence of a highly conserved J domain 
 Recruitment of client proteins for 
Hsp70 
(Cyr and Douglas, 
1994; Cyr et al., 1994) 
60 kDa Heat 
Shock Protein 
Hsp60 GroEL 
 Forms a ring-shaped oligomeric protein complex 
with a large central cavity 
 Also known as chaperonin which is the non-heat 
inducible form of Hsp60  
 In bacteria, it requires GroES to assist in its functions 
 Chaperone a large variety of newly 
synthesized and newly translocated 
proteins to their native state 
 
 
(Bukau and Horwich, 
1998; Fink, 1999) 









 Consists of two functional domains  
 The N-terminal domain binds and hydrolyzes ATP   
 C-terminal domain is responsible for substrate-
binding  
 Undergoes ATP-induced conformational changes  
 Functions are modulated by chaperones such as 
Hsp40 
 Involves in de novo folding of 
nascent polypeptide chains on 
ribosomes 
 Chaperone newly translocated 
protein  
(Cyr and Neupert, 
1996; Fink, 1999) 










 Highly abundant in the cells 
 Undergoes ATP-induced conformational changes  
 
 Regulates the activity of proteins 
involved in signal transduction 
pathways such as kinases steroid 
receptors and transcription factors 
(Wandinger et al., 
2008) 
100 kDa Heat 
Shock Protein 
Hsp100, Hsp104 ClpB, ClpA, ClpX 
 Forms a caseinolytic protease complex  Involved in protein unfolding and 
degradation 
(Schirmer et al., 
1996) 
110 kDa Heat 
Shock Protein 
Hsp110  
 Diverged relative of Hsp70   Act as a nucleotide exchange factor 
for Hsp70  
(Andreasson et al., 
2008) 
1 Endoplasmic reticulum 
2 Mitochondria 





Figure 2.1: Hsp90 and the Hallmarks of Cancer. A diverse array of proteins required Hsp90’s chaperone activity for 
activation. They include transcription factors, cell cycle regulators and kinases (www.picard.cn). Importantly, many of 
these proteins are oncoproteins which drives the hallmarks of cancer (Hanahan and Weinberg, 2011). Therefore, Hsp90 
has emerged as a promising molecular target/biomarker for cancer therapy. 
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2.3 Structure and Function of Heat Shock Protein 90 
A current search in the Research Collaboratory for Structural Bioinformatics (RCSB) protein 
database revealed over 100 crystal structures of Hsp90. The full crystal structure of yeast Hsp90 with 
the deletion of the linker region (the 34 amino acid residues), was solved in 2006 (Ali et al., 2006). 
The structure of Hsp90 was found to consist of three flexibly linked domains, a ~25kDa N-terminal 
ATP/ADP-binding domain, a proteolytic resistant middle domain, and a ~55 kDa C-terminal domain 
responsible for Hsp90 dimerization (Figure 2.2). In addition, there is a linker region connecting the N-
terminal domain with the middle segment. This flexible region varies in length and composition 
among various species and isoforms (Pearl and Prodromou, 2006).  
2.3.1 Hsp90 N-terminal Domain: ATP/ADP-Binding Pocket 
The N-terminal domain of Hsp90 is a two-layer structure where the ATP/ADP binding pocket 
is sandwiched between the hydrophobic face of highly twisted anti-parallel β-sheets and nine α-
helices (Figure 2.3). This unique glycine-rich ATP/ADP binding motif known as the Bergerat fold, is 
highly conserved in all Hsp90s and is present in the N-terminal domain of type II DNA 
topoisomerases and the MutL DNA mismatch repair proteins (Dutta and Inouye, 2000). This 
similarity has led to the classification of Hsp90 as part of the GHKL ATPases superfamily. 
Interestingly, this unusual binding pocket possesses no similarity with ATP binding domains found in 
other kinases or Hsp70. The crystal structure showed that the adenosine nucleotide (ADP/ATP) 
assumes an unusual compacted conformation, which brings the sugar and α-phosphate group into 
close proximity to the five-membered ring of the adenine. Furthermore, it revealed that Hsp90 
inhibitors such as geldanamycin and radicicol are able to mimic the structure of adenosine 
nucleotide and bind to this atypical ATP-binding pocket (Roe et al., 1999; Stebbins et al., 1997) which 
allows specific inhibition of Hsp90. 
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2.3.2 Hsp90 Middle Domain: Proposed Client Protein Binding Domain 
The middle segment has a hydrophobic region that revolved around the amino acid residue, 
Trp300 and an unusual amphipathic protrusion (Meyer et al., 2003). These distinctive features could 
play a role in protein-protein interaction and thereby, are suggested to be a major interaction site 
for Hsp90 client proteins. In addition, similar to other GHKL ATPases such as MutL and GyrB, the 
hydrolysis of ATP in Hsp90 requires a catalytic residue from the middle region of the molecular 
chaperone to proceed (Figure 2.2). Alignment of the GHKL ATPase family identified a conserved 
lysine residue (Lys307 in MutL; Lys337 in GyrB) which is situated in a loop that extends out from the 
αβα domain of the middle segment (Dutta and Inouye, 2000). This residue interacts with the γ-
phosphate of an ATP molecule bound in the N-terminal domain and thus, catalyzes the hydrolysis of 
ATP. Surprisingly, this residue is not present in Hsp90. Instead, a conserved arginine, Arg380 (yeast 
Hsp82 numbering) was identified to play a similar role to that of the lysine residue. Mutagenesis 
study had shown that Arg380 is essential for the ATPase activity in Hsp90 and more critically, the 
functions of Hsp90 in yeast (Meyer et al., 2003). A co-chaperone protein, Aha1, was also found to 
interact with the catalytic loop bearing Arg380 (Meyer et al., 2004). This protein is implicated in 
Hsp90 client protein activation and stimulation of ATPase activity (Panaretou et al., 2002).  
2.3.3 Hsp90 C-terminal Domain: Interface for Dimerization and Interaction with co-
chaperones 
The highly conserved C-terminal domain (Figure 2.2) has a conserved EEVD motif which 
serves as an interface point for binding various co-chaperones that possess the tetratricopeptide 
repeat (TPR) domain. The substitution of EEVD to AAVD was shown to greatly affect the interaction 
between Hsp90 and TPR-domain-containing co-chaperone (Chen et al., 1998). Similarly, in another 
study, yeast two-hybrid experiments established that the C-terminal domain of Hsp90 was the 
binding site for TPR-domain containing proteins and co-chaperones (Young et al., 1998). These 
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important co-chaperones are required to aid Hsp90 in the folding and/or activating of its client 
substrates. One of the well-characterized co-chaperones that interact with the C-terminal of Hsp90 
is the TPR-domain containing Hsp70-Hsp90 organizing protein (Hop) Besides serving as the site for 
the co-chaperone interaction, C-terminal domain also forms the interface which allows a pair of 
monomer Hsp90 to interact and dimerize (Harris et al., 2004). The dimerization of the Hsp90 was 
























Figure 2.2: Schematic Diagram of Hsp90 Structure.  Hsp90 consists of three domains, namely the N-terminal domain, middle segment and C-
terminal domain. The N-terminal domain is connected to the middle segment via the charged linker. The charged linker region varies in length 
and composition among various species and isoforms. The different domains of Hsp90 contribute to the overall function of the Hsp90 through 
their respective roles as illustrated in the diagram. The crystal structures were obtained from RCSB Protein Data Bank, using the respective PDB 
ID indicated above.  





Figure 2.3: N-terminal Domain of Hsp90. The Hsp90 has a unusual ATP/ADP binding pocket known as the Bergerat 
fold which allows ATP (depicted in red) to bind. Hsp90 inhibitors such as geldanamycin (depicted in orange) are able 
to mimic the structure of adenosine nucleotide and bind to the ATP/ADP binding pocket. The crystal structures were 
obtained from RCSB Protein Data Bank, using the respective PDB ID indicated above. It was viewed using Swiss-
PdbViewer DeepView v4.1.  
Hsp90 with ATP (PDB: 1AM1) Hsp90 with geldanamycin (PDB: 1YET) 
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2.4 Role of Hsp90 in Protein Folding and Activation 
The protein folding pathway mediated by Hsp90 is a complicated and complex process 
which, to some extent, remains elusive. Based on the well-characterized steroid receptor maturation 
model, Hsp90 requires the cooperative action from a set of partner proteins, as on its own, Hsp90 is 
unable to promote the folding of its known client proteins in vitro. Hsp90 assembles with other 
chaperones such as Hsp40, Hsp70 and co-chaperones to form multi-chaperone machinery necessary 
for the folding or activation of client proteins. During the chaperoning of its client protein, Hsp90 
undergoes conformational changes which are governed by the binding and hydrolysis of ATP 
(Prodromou et al., 2000).  
Stepwise assembly experiments revealed that the process of chaperoning the steroid 
receptor begins with Hsp40 binding to the receptor hormone binding domain (Hernandez et al., 
2002; Pratt and Toft, 2003)(Figure 2.4). This, in turn, recruits Hsp70 to form the early complex. 
Subsequently, upon the hydrolysis of ATP by Hsp70, Hop and Hsp70 interacting protein (Hip) begin 
to associate with the complex to form an intermediate complex. Yeast two-hybrid study had 
demonstrated that Hip interacts with the ATPase domain of Hsp70 to stabilize the ADP state of 
Hsp70 which has a high affinity for substrate binding (Demand et al., 1998). The other co-chaperone, 
Hop, is to act as a mechanical linker to bring Hsp90 to the receptor-Hsp70 complex and subsequently 
allows the client proteins to be transferred to the newly recruited chaperone via an uncharacterized 
mechanism. Hop has the ability to simultaneously bind to Hsp90 and Hsp70 because it has multiple 
TPR motifs that interact with the C-terminal EEVD motifs of both chaperones (Smith et al., 1993).  
 The chaperone pathway enters the final phase with Hsp70 and Hop dissociating 
from the complex in exchange for co-chaperones such as p23 and Cdc37 that are specific for 
individual client proteins. Hsp90 will subsequently undergo a conformational cycle in order to 
activate the client protein. This conformational process is tightly regulated by Hsp90’s ability to bind 
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and hydrolyze ATP. Therefore, the ATPase activity of Hsp90, indirectly, drives its functionality as a 











Figure 2.4: Proposed Model of Steroid Hormone Receptor Maturation Pathway. Maturation of Hsp90 client 
protein is a highly ordered process with various chaperones and co-chaperones participating at different 
phases. This cycling reflects the role of different chaperones and co-chaperones in the folding process. The 
folding pathway begins with Hsp40 binding to the client protein (2). Subsequently, Hsp70 is recruited to form 
the early complex (3). The association of Hsp90, Hop and Hip with the Hsp70-complex would result in the 
formation of intermediate complex (4). The final maturation of its client proteins is mediated by Hsp90, which 
cooperates at this stage with p23 (5). The release of client protein by Hsp90 required the hydrolysis of ATP. 
Therefore, the cycle is tightly regulated by ATPase activity of Hsp90 (Caplan et al., 2003). 
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2.5 ATPase Activity of Hsp90: Mechanism of Inhibition 
During the process of protein maturation, Hsp90 undergoes a series of conformational 
transformation, transiting between an open hydrophobic state and a close conformation (Trepel et 
al., 2010). These structural changes operate in a cycle, orchestrated by the binding and hydrolysis of 
ATP at the binding pocket located at its N terminal domain. As a result, Hsp90’s ATPase activity is 
tightly coupled to its function as a chaperone. Regulatory proteins, such as co-chaperones, are able 
to influence Hsp90’s function through modulating the ATPase activity of Hsp90.   
ATP binding and hydrolysis drive Hsp90 to undergo a conformation cycle which transits 
between an open hydrophobic state and a close conformation (Sullivan et al., 1997). It was 
proposed that this structural transition regulates Hsp90’s interaction with its client proteins 
(Wandinger et al., 2008; Young and Hartl, 2000; Young et al., 2001). This highly dynamic 
conformational shift allows Hsp90 to recognize its vast client repertoire. Hsp90 operates as a 
homodimer where two Hsp90 monomers interact together via their C-terminal domains. Upon the 
binding of ATP to Hsp90, a short segment of the N-domain known as the “ATP lid” will change its 
position and flap over the ATP binding pocket (Figure 2.5). Subsequently, the first 24 amino acid 
residues at the N-terminal of each Hsp90 monomer interact with each other and form a transient N-
terminal dimerized conformation (Richter et al., 2006). This N-terminal rearrangement results in 
further conformational alternation throughout the entire Hsp90 dimer, leading to a twisted and 
compacted dimer, in which N- and M-domains associate and the distance between M-domains is 
shortened by 40 Å (Wandinger et al., 2008). The association of N- and M-domains completes the 
catalytic sites for ATP hydrolysis (Ali et al., 2006; Richter et al., 2006; Wandinger et al., 2008). Upon 
the hydrolysis of ATP, Hsp90 returns to its initial open conformation and releases the activated client 
proteins (Young and Hartl, 2000; Young et al., 2001). This completes the activation pathway of 
Hsp90’s client proteins. 
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The Hsp90 inhibitors such as geldanamycin and radicicol are able to inhibit Hsp90’s function 
by competing with ATP to bind at the N-terminal nucleotide binding pocket of Hsp90. The inability of 
Hsp90 to utilizes the energy from ATP to induce the necessary structural changes lead to the 
abrogation of the chaperone cycle. This results in the lost of functionality of Hsp90 and 





















Figure 2.5: ATPase Cycle of Hsp90. Upon ATP binding (2), the ATP lid at the N-domain of Hsp90 closes the ATP binding pocket (3). 
Subsequently, the first 24 amino acids of the N-terminal of each Hsp90 monomer interact with each other and form a transient N-terminal 
dimerized conformation (4). It would result in further conformation rearrangement and lead to compaction of Hsp90 dimer. This 
completes the ATP catalytic sites that are required for ATP hydrolysis. After ATP hydrolysis (5), Hsp90 will return to its initial open 
conformation and release the matured client protein (1) (Wandinger et al., 2008). Evidence of the open and closed conformation of Hsp90 
is provided by crystallographic studies on E. coli HtpG (PDB: 2IOQ) and yeast Hsp82 (PDB: 2CG9) respectively. 
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2.6 Current Status of Hsp90 inhibitors in Clinical Trials 
There are two known naturally occurring specific inhibitors of Hsp90, namely geldanamycin 
and radicicol that are produced by Streptomyces hygroscopicus and Humicola fuscoatra respectively. 
As geldanamycin and radicicol are highly toxic and unsuitable for clinical trials, new analogues of 
geldanamycin and radicicol with favourable toxicity profile and improved solubility were developed 
through synthetic chemistry (Pacey et al., 2006)(Figure 2.6). Currently, there are around 20 Hsp90 
inhibitors undergoing clinical trials for cancer treatment (Kim et al., 2009; Neckers and Workman, 
2012)(Figure 2.7) (Table 2.2). The 2 main groups of the Hsp90 inhibitors are 1) geldanamycin 











Figure 2.6: Chemical Structure of Geldanamycin and Radicicol. Geldanamycin contains a quinone group 
(depicted in red) that lead to in vivo instability and/or to off-target toxicities. Radicicol is a chemically distinct 
from geldanamycin and its core element is the resorcinol moiety (depicted in green) which is important for 
the binding to Hsp90. The crystal structures were obtained from RCSB Protein Data Bank, using the respective 
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2.6.1 Geldanamycin Derivatives: First Type of Hsp90 inhibitor to Enter Clinical Trial  
 17-AAG (17-allyl-17-demethoxygeldanamycin) is derived from a substitution in the 
geldanamycin’s methoxy group with an allylamino group. It has similar activity against Hsp90 but 
with an improved toxicity prolife as compared to geldanamycin. Being the first Hsp90 inhibitor that 
underwent clinical evaluation, 17-AAG has thus far been demonstrated to have clinical activity 
against HER2+ breast cancer and multiple myeloma in combination with trastuzumab and 
bortezomib respectively (Modi et al., 2011; Richardson et al., 2010). 
Apart from 17-AAG, 2 other GA derivatives, 17-DMAG (17-desmethoxy-17-N,N-
dimethylaminoethylaminogeldanamycin) and IPI-504 (water-soluble hydroquinone hydrochloride 
salt derivative), had been developed. 17-DMAG contained a substitution of the C-17 methoxy group 
of geldanamycin with N, dimethylethylamine has improved water solubility, better oral 
bioavailability and equal or greater anti-tumour activity as compared to 17-AAG. As for IPI-504, it 
was predicted to result in lower hepatotoxicity due to the lack of quinone (Solit and Chiosis, 2008). 
Although no further investigation was carried out to compare the hepatotoxicity between the IP-504 
and other GA derivatives, recent concluded trial indicated that IPI-504 exhibited a favourable toxicity 
profile with no observed adverse effect (Sequist et al., 2010). The advancement of Hsp90 inhibitors 
suggests that toxicity and undesired side effects of Hsp90 drug that was observed in the early clinical 
trials could be circumvented.  
2.6.2 Radicicol Derivatives: Chemically Distinct Group of Hsp90 Inhibitor 
As radicicol is highly unstable in serum, studies had indicated that radicicol lacks the 
inhibitory activity against cancer in vivo. Nevertheless, this group of inhibitors remains attractive for 
development as it is chemically distinct from geldanamycin derivatives. The absence of a quinone 
ring in radicicol indicated that the inhibitor is unlikely to cause hepatoxicity as observed in the use of 
geldanamycin/derivatives (Figure 2.6). This would be a valuable additional tool to investigate the 
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functionality of Hsp90. Indeed, about 7 years after the first Hsp90 inhibitor clinical trial, radicicol 
derivatives, which have a characteristic resorcinol core that is critical for binding to Hsp90, had been 
developed and underwent clinical testing. An important inhibitor of this class is triazole derivatives 
STA-9090. It was currently tested in multiple clinical trials in both the advanced solid and 
haematological tumours (Choi and Lee, 2012). In the recent concluded trial, STA-9090 had showed 
clinical activity or at least disease stabilization in patients with advanced lung cancer, especially in a 
cohort that was molecularly defined with ALK gene rearrangement (Socinski et al., 2013). 
2.6.3 The Complexity of Targeting Hsp90 For Cancer Treatment 
The rationale of targeted cancer therapies is to neutralize specific molecules such as driver 
oncogenes that are deemed most susceptible in disrupting the highly complex signaling pathways 
and networks that promote malignancy. Hsp90 inhibitor is predicted to have high efficacy against a 
diverse range of cancers as it interferes with numerous oncogenes that drive the multifaceted 
disease. Unfortunately, from many concluded clinical studies, Hsp90 inhibition did not meet the 
expected clinical activity extrapolated from the favorable pre-clinical data. It also failed to achieve 
uniform cytotoxicity towards cancer. Instead, certain subset of cancers such as HER+ breast cancer is 
somewhat more susceptible to Hsp90 inhibition as compared to other such as melanoma carcinoma 
with BRAF mutation (Modi et al., 2011; Solit et al., 2008; Travers et al., 2012). This suggested that 
the molecular features of individual cancer are a paramount factor for consideration in future clinical 
tests for Hsp90 inhibitor. 
Currently, predicting specific cancer susceptibility to Hsp90 inhibition is to probe for certain 
key Hsp90 client proteins in malignant cells. However, the lack of clinical benefit in prostate cancer 
patients even with the abrogation of several Hsp90 client proteins’ activity, including androgen 
receptor (AR) that are crucial for disease progression, suggests that there is a need to re-examine 
such an approach (Centenera et al., 2013). Retrospectively, Hsp27 expression was found to be 
Chapter 2 Literature Review 
41 
 
upregulated through Hsp90 inhibition. With Hsp27 found to stabilize AR, it may have antagonized 
the expected anti-cancer activity of Hsp90 inhibitors (Zoubeidi et al., 2007). Perhaps, in the case of 
the prostate cancer, other pathways attributing to malignancy might have unknowingly been 
overlooked and the adaptability of cancer to trigger compensating pathway to circumvent the 
detrimental effect of Hsp90 inhibition is underestimated. Given that targeting Hsp90 has far-
reaching implications, a more global approach of analyzing the response of cancer cells towards 







Figure 2.7: Timeline of Hsp90 Inhibitors Development and Landmark Findings (Adapted from  
Kim et al., 2009). 
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2.7 Specificity of Hsp90 inhibitors to its Target 
Hsp90 inhibitors such as geldanamycin and radicicol had been greatly used as a tool to 
validate the role of Hsp90 in cancer, as the deletion of the gene for Hsp90 was lethal to eukaryotes.  
Hsp90 was first uncovered as the specific target of geldanamycin, using the solid-phase binding assay 
where geldanamycin was covalently coupled to the beads (Grenert et al., 1997). Silver staining of the 
cell lysate that was incubated with geldanamycin bounded beads revealed a single protein band that 
was subsequently identified as Hsp90 through immunoblotting. Similarly, radicicol was discovered to 
inhibit Hsp90 using competitive binding assay (Schulte et al., 1998). Both the inhibitors were co-
crystallized with the N-terminal domain of Hsp90 and were found to bind at the ATP-binding site of 
chaperone. Using isothermal titration calorimetry, geldanamycin and radicicol were shown to have 
high binding affinity to Hsp90 with a Kd of 1.2 μM and 19 nM respectively (Roe et al., 1999). The 
crystallographic study also revealed that the Hsp90 possessed an atypical ATP-binding pocket and 
both the Hsp90 inhibitors are able to induce major favorable enthalpy changes when binding to the 
chaperone. The high specificity property of the Hsp90 inhibitors not only presents a valuable tool to 
investigate the role of chaperones in cellular function and more importantly, to target cancer cells.  
2.8 Roles of Hsp90 in Cancer Development 
Hsp90 plays an important role in cancer development and malignancy as it helps to 
chaperone a large number of overexpressed oncoproteins (Trepel et al., 2010). These oncoproteins, 
which drives the hallmarks of cancer, include Akt, survivin, VEGF, p53 and telomerase (Figure 2.1). 
Importantly, many of these oncoproteins are mutated and therefore, are structurally more unstable 
and easily misfolded. Consequently, these oncoproteins are more dependent on Hsp90 for stability 
and activity (Whitesell and Lindquist, 2005). 
Besides maintaining the oncoproteins in cancer, Hsp90 also helps the cancer cells to cope 
with cellular stress. As cancer cells proliferate rapidly, they need to handle a greater amount of 
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stress such as hypoxia, nutrient deprivation and acidosis. Furthermore, the instability of genome in 
cancer cells such as aneuploidy, gene copy number variation, chromosomal translocation and 
missense mutations would result in an increase amount of proteins that are at suboptimal stability. 
Thus, cancer cells arguably would constantly engage the Hsp90 in its activated state to deal with the 
high level of stress.   
Despite that Hsp90 is recognized as a potential therapeutic target for HCC, the roles of 
Hsp90 in HCC pathogenesis remain to be fully elucidated (Figure 2.8). Hsp90 were found to be 
elevated at the protein level in the tumours of HCC patients (Lim et al., 2005; Lim et al., 2002). 
Furthermore, the expression of Hsp90 correlated with the survival of HCC patients (Pascale et al., 
2005). These suggested that Hsp90 may have an important role in the development of HCC. 
Subsequent in vitro studies found that Hsp90 inhibitors were able to inhibit cell growth through cell 
cycle arrest and inducing apoptosis in HCC cells (Breinig et al., 2009; Watanabe et al., 2009). In the 
xenograft model, Hsp90 inhibitors were shown to reduce tumour volume (Breinig et al., 2009; 
Watanabe et al., 2009). However, only a number of oncoproteins such as hepatocyte growth factor 
receptor, protein kinase B, cyclin-dependent kinase 4, survivin, cyclin D1 and Raf-1 were found to be 
deregulated by Hsp90 inhibitors in the HCC cells. Therefore, the molecular basis of the cellular 










2.9 Pathogenesis of Hepatocellular Carcinoma 
Hepatocarcinogensis is a multistep process characterized by sequential mutation on a 
number of genes which are generally involved in proliferation and/or apoptosis (Farazi and DePinho, 
2006). Several risk factors such as hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, 
aflatoxin b1 exposure and excessive alcohol intake are known to be associated with HCC (El-Serag 
and Rudolph, 2007). Although the causative agents may be diverse in nature, the development of 
HCC converges at chronic inflammation, continuous rounds of necrosis and regeneration, and 
oxidative stress undergoes by hepatocytes. The histopathology of the disease begins from 1) chronic 
hepatitis, 2) liver cirrhosis, 3) hyperplastic nodules, 4) dysplastic nodules and finally 5) HCC (Figure 
2.9).  
Figure 2.8: A Summary of the Roles of Hsp90 in HCC and the Gene Expression Profiling of Cancer Cells 
Treated with Hsp90 Inhibitors 
1 Lim et al., 2002, 2 Lim et al., 2005, 3 Breinig et al., 2009, 4 Watanabe et al., 2009, 5 Sun et al., 2010, 
6 Leng et al., 2012, 7 Clarke et al., 2000, 8 Maloney et al., 2007, 9 Zajac et al., 2010 
*2-DE (Two-dimensional gel electrophoresis) 
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The molecular mechanisms involved in the development and progression of HCC are still 
largely elusive. Thus far, the key common pathogenetic pathway of hepatocarcinogensis is the 
inactivation or mutation of p53. However, whether p53 mutation contributes to the initiation and/or 
progression of HCC remains an area of active investigation. Nevertheless, with mutations in p53 only 
detected in larger HCCs, it suggests that the inactivation of p53 is associated with progression to 
late-stage disease.  
Besides the inactivation of p53, several molecular pathways that regulates proliferation and 
cell death are also implicated in the hepatocarcinogensis (Whittaker et al., 2010). Among them is the 
MAPK pathways which is shown to be activated by both HBV and HCV (Panteva et al., 2003)). The 
MAPK cascade is essential signaling pathways that regulate cellular growth and differentiation in the 
eukaryotes in response to extracellular stimuli such as growth factors and cytokines (Pearson et al., 
2001). Each MAPK pathway consists of three main components which are 1) MAPK kinase (MAP3K), 
2) MAPK kinase (MAP2K), and 3) MAPK. In human, the proteins involved in this pathway are namely; 
RAF-1 (MAP3K), MEK-1/2 (MAP2K) and ERK-1/2 (MAPK). The signaling cascade is activated through 
tyrosine kinases receptors such as EGFR, IGFR, platelet-derived growth factor receptor (PDGFR) and 
vascular endothelial growth factor receptor (VEGFR). The activated receptors, in turn, 
phosphorylated Ras (Ras-GTP) to triggers the sequential activation of RAF-1, MEK-1/2, and ERK-1/2. 
The activated/phosphorylated ERK1/2 will then translocate into the nuclei and activate transcription 
factors such as c-JUN, c-FOS, c-MYC to promote cell proliferation and differentiation. 
In HCC, Ras protein is found to be mutated and activated in 30% of HCC. Overexpression of 
Raf kinases is also found in the majority of HCC (Downward, 2003). Moreover, expression of growth 
factors such as HGF, EGF, VEGF and PDGF is generally elevated in HCC and therefore, maintain the 
MAPK cascade in a constituently activated mode. Clinically, the size and malignancy of the HCC 
tumour were found to correlate with the activity of the MAPK pathway which suggests the 
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importance of MAPK pathway in HCC progression (Ito et al., 2001; Schmitz et al., 2008). More 
importantly, a multi-kinase inhibitor, Sorafenib, is the first FDA approved drug for the treatment of 
advanced HCC (Ben Mousa, 2008). Thus, drugs with the ability to abrogate the activated MAPK 
pathway in HCC hold yet another promise in stopping the disease progression. 
 
 




 Figure 2.9: Pathogenesis and the Molecular Features of HCC: Major risk factors of HCC is hepatitis B virus (HBV) infection, hepatitis C 
virus (HCV) infection, aflatoxin b1 exposure and excessive alcohol intake. The disease begins with chronic inflammation, continuous 
rounds of necrosis and regeneration which leads from chronic hepatitis, to liver cirrhosis, hyperplastic nodules, dysplastic nodules and 
finally HCC. Besides the loss of p53, activation of MAPK pathway is also known to to occur during HCC development. Events which 
results in activating MAPK pathway or as a consequence of the activated signalling cascade is decipted in red. (Adapted with permission 
from Farazi and DePinho, 2006, Appendix E) 
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Chapter 3: Materials and Methods 
3.1 Mammalian Cell Culture and Assays 
3.1.1 Mammalian Cell Culture 
All cell lines used in this project were obtained from American Type Culture Collection (ATCC, 
Manassas, VA) and Japan Health Science Research Resources Bank. Human HCC cell lines HepG2 
(p53 wild-type) and HuH-7 (p53 mutant) were cultured in Dulbecco’s Modified Eagle Medium 
(Gibco/Invitrogen) supplemented with 10% FBS. Non-transformed immortalized human liver cells 
NeHepLxTH (ATCC CRL-4020) were cultured in Dulbecco's Modified Eagle Medium: Nutrient Mixture 
F-12 (DMEM/F-12) Media supplemented with 10% FBS, 0.1 μl/ml dexamethasone, 0.11 μl/ml insulin 
and 50 μg of G-418. Flasks and plates used for propagation of NeHepLxTH cells were coated with 
0.03 mg/ml rat tail collagen type I. All cells were incubated in a humidified atmosphere at 37˚C, 5% 
CO2.  
3.1.2 Transient Transfection Methods and Cell Profile Assay 
3.1.2.1 Cell Validity Assay 
WST-1 reagent (Roche) was used to assay the viability of cells. Briefly, 3 x 103 cells were 
seeded in each well of a 96-well plate. Various concentrations of 17-AAG (LC Laboratories) and 
radicicol (Sigma) were introduced to the cells 24 hr post-seeding. After 48 hrs of treatment, 10 μl 
WST-1 reagent (Roche) were added to each well that were pre-washed with PBS and replaced with 
fresh culture media. Absorbance change made to each well after 1 hr was detected using the multi-
detection monochrometer microplate reader (Tecan) at 440 nm.  
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3.1.2.2 Profiling Hsp90 Inhibitors induced Apoptosis  
5 x 105 HuH-7 and HepG2 cells were treated with various concentrations of Hsp90 inhibitors 
(17-AAG [LC Laboratories] and radicicol [Sigma]) or control vehicle DMSO for 48 hrs. The apoptosis 
profiles of the cells were analyzed by PE Annexin V and 7AAD staining according to the 
manufacturer’s protocol (BD Biosciences Pharmingen™), followed by flow cytometry using the BD 
FACSCalibur™ (BD Biosciences). Subsequent analysis of the cellular profiles was performed using 
FlowJo software with appropriate compensation (Tree Star, Inc). 
3.1.2.3 Caspase Activity Assay 
5 x 105 HuH-7 cells were treated with either 0.1 μM of 17-AAG, 1 uM of 17-AAG, 50 μM of 
HSP90AA1 and HSP90AB1 specific siRNAs, DMSO or negative control siRNA (Ambion). After 48 hrs of 
treatment, lysate of cells were obtained. To assay for the different caspases’ activity, caspase 
specific fluorometric substrate (BioVision Inc) was used (Table 3.1). 5 μl of caspase-specific 
fluorometric substrate were incubated with 50 μg of the cell lysate. Absorbance change made to 
each reaction for every 10 min over a period of 2 hrs was detected using the multi-detection 







Table 3.1 – Caspase Specific Fluorometric Substrates 
Caspases Substrates 
Caspase 3 Ac-DEVD-AFC 
Caspase 6 Ac-VEID-AFC 
Caspase 8 Ac-IETD-AFC 
Caspase 9 Ac-LEHD-AFC 
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3.1.2.4 Chemical Transfection of siRNA in HuH-7 Cells 
5 x 105 cells were seeded into each well of the 6-well plate. 50 nM of short interfering RNAs 
(siRNAs) were chemically introduced to the cells 24 hr post-seeding using siPORT™ Amine 
Transfection Agent (Ambion) according to the manufacturer’s protocol. Briefly, 5 μl of siPORT™ 
Amine Transfection Agent was diluted in 100 μl of OPTI-MEM I® (Invitrogen) reduced serum media 
and incubated for 10 min at room temperature. Separately, siRNA was appropriately diluted in 100 
μl OPTI-MEM. Diluted siPORT™ Amine Transfection Agent was subsequently mixed with the diluted 
siRNA by gentle pipetting up and down, and incubated for 10 min at room temperature. The nucleic 
acid/ siPORT™ Amine transfection complexes were then added onto the adherent cells that were pre-
washed with PBS and replaced with fresh culture media. Cells were harvested 48 hr post-
transfection. siRNAs specific for HSP90AA1 (s6994), HSP90AB1 (S6999) as well as negative control 
scramble siRNA (AM4611) were purchased from Ambion.  
3.1.2.5 Cell Proliferation Assay 
Approximately 3 x 103 of HuH-7 or HepG2 cells were seeded into a 96-well plate. Various 
concentrations of 17-AAG (LC Laboratories) or radicicol (Sigma) were added into each individual well. 
Vehicle control DMSO was added to the control group. Using a live cell imagery system IncuCyte 
ZOOM (Essen Instruments), 4 fixed field images were taken from each individual well at a 2 hr 
interval. From the images taken, the system measured the confluency of each well. The rate of 
growth for each cell treated at various dose of Hsp90 inhibitor was calculated based on the increase 
in cell confluency relative to time 0 hr. 
3.1.2.6 Wound-Healing Assay 
Approximately 1 x 104 of HuH-7 or HepG2 cells were seeded into a 96-well plate to form a 
confluent mono-layer of cells. A precise and reproducible wound was created in each of the well 
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using the 96-pin WoundMaker (Essen Instruments). After washing twice with PBS, various 
concentrations of 17-AAG (LC Laboratories) or radicicol (Sigma) were added into each individual well. 
Vehicle control DMSO was added to the control group. The width of each of the wound was 
monitored every 2 hr for a period of 60 hr using the live cell imagery system IncuCyte ZOOM (Essen 
Instruments). The rate of cell migration was determined by the extent of wound closure. 
3.1.2.7 Analysing tert-butyl hydroperoxide Induced Apoptosis 
Approximately 3 x 105 of HuH-7 and HepG2 cells were seeded into a 6-well plate and 
incubated overnight. The cells were pre-treated with either 17-AAG or radicicol at two different 
concentrations of 0.1 μM and 1 uM for 48 hrs. Following which, the different stated doses of tert-
butyl hydroperoxide (tBHP, Sigma) were added the respectively cell lines and incubated for 4 hrs to 
induce cell death via oxidative stress. The amount of cell death was measured using two different 
methods. In the first method, cells were stained with Hoechst 33258 and TMRE to analyze the cells’ 
nuclear morphology and mitochondrial membrane potential respectively. As apoptotic cell will 
display nuclear condensation and loss its mitochondrial membrane potential, viable cells will be 
stained with TMRE and less intense Hoechst 33258 staining whereas cell undergoing apoptosis will 
have intensified Hoechst 33258 staining but not be stained with TMRE. In the second method, the 
cells were analyzed by using flow cytometry with PE Annexin V and 7AAD staining as mentioned in 
the Section 3.1.2.2. 
3.2 RNA Methodology 
3.2.1 RNA Isolation and Reverse Transcription Polymerase Chain Reaction 
Total RNA was isolated from cells using RNeasy® Mini Kit (Qiagen, Hilden Germany) according 
to the manufacturer’s instructions. The amount of RNA was quantified using NanoDrop™ 1000 
Spectrophotometer (Thermo Scientific). The total RNA was subsequently treated with RQ1 RNase-
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Free DNase (Promega). First-strand cDNA synthesis was carried out according to the manufacturer’s 
instructions. A 12 μl reaction volume comprising 1 μg RNA, 1 μl 50 μM oligo dT primers, 1 μl 10 mM 
dNTP and RNase/nuclease free water was first heated to 65°C for 5 min and put on ice for 5 min. 
Following which, 4 μl 5 X First-strand buffer, 2 μl 0.1 M DTT, 1 μl RNase/nuclease free water and 1 μl 
SuperScript® II Reverse Transcriptase (Invitrogen) were added to each tube. The tubes were mixed 
and incubated at 25°C for 5 min followed by 42°C for 60 min and 70°C for 15 min. 
 
3.2.2 Real-time Polymerase Chain Reaction 
Transcript abundance was determined by quantitative real-time PCR (qPCR) using CFX96 
C1000™ Real-Time PCR Detection System (Bio-Rad Laboratories). A 10 μl reaction volume was 
prepared comprising of 5 μl QuantiTect™ SYBR® Green Master PCR mix (Qiagen), 0.2 μl each of 
forward and reverse primers (Table 3.2), 3.6 μl deionised water and 1 μl cDNA. The following qPCR 
reaction conditions were used: an initial denaturation step at 95°C for 10 min, followed by 45 cycles 
of 95°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec. All transcript abundance was normalized 

























3.2.3 Agarose Gel Electrophoresis 
DNA was mixed with 6 X DNA loading dye (0.1% bromophenol blue, 40% sucrose, 240 mM Tris-
HCL pH7.4, 60 mM EDTA-Na pH8.0) and separated on a 1% agarose gel prepared by dissolving 
agarose in 1X TAE buffer (0.04 M Tris-acetate, 0.001 M EDTA) with addition of 0.5 μg/ml ethidium 
bromide. The gel was run using 1 X TAE buffer, at 120 volts. DNA bands were visualized using a UV 
trans-illuminator. 
 
Table 3.2 – List of Primers used 
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3.3 Protein Methodology 
3.3.1 Protein Isolation from Cells and Quantification of Protein Concentration 
Cell pellets were lysed with 100 µl RIPA buffer (50 mMTrisHCl pH 8, 150 mMNaCl, 1% Igepal 
CA-630, 0.5% sodium Deoxycholate, 0.1% SDS) and incubated on a rotating platform for 10 min at 
4ºC. Cells were sonicated using a Bioruptor® (Diagenode Denville) for 10 min at high setting, 30 sec 
‘on’ followed by 30 sec ‘off’. Cell debris was removed by centrifugation at 13,000 rpm for 30 min at 
4ºC and cell lysates were transferred to new tubes. Protein concentrations were determined using 
BCA protein assay reagent (Pierce) according to the manufacturer’s instructions.  
3.3.2 Western Blotting 
10 μg of protein from each sample was mixed with 6 X loading buffer, boiled for 10 min and 
subjected to gel electrophoresis on a 10% SDS poly-acrylamide gel. Following transfer to a 
polyvinylidene fluoride membrane (Bio-Rad), blots were blocked for 1 hr using Amersham ECL™ 
membrane blocking agent (GE Healthcare Biosciences,). The appropriate primary antibodies (Table 
3.3) were then added to the blot and incubated for 1 hr at room temperature or overnight at 4˚C. 
Blots were washed with PBST for 10 min and then incubated for 60 min with the appropriate 
horseradish peroxidise-conjugated secondary antibodies (Table 3.4). Following the washing, signals 
were detected using Amersham ECL™ Western Blotting Detection Reagents (GE Healthcare). The 



























Table 3.3 – List of Primary Antibodies used 
Primary Antibodies Manufacturers Cat. No Dilution Isotype 
BCL-2 BD Biosciences 75167 1:10,000 Mouse IgG 
Caspase 8 Santa Cruz Sc-5263 1:1000 Mouse IgG 
Caspase 9 Santa Cruz Sc-17784 1:1000 Mouse IgG 
GAPDH Millipore ABS16 1:20,000 Rabbit IgG 
Hsp70 Santa Cruz Sc-24 1:10,000 Mouse IgG 
Hsp90 Stressgen SPA-835 1:10,000 Rat IgG 
SOD Santa Cruz Sc-8637 1:1000 Goat IgG 
Table 3.4 – List of Secondary Antibodies used 
Primary Antibodies Manufacturers Dilution Isotype 
Anti Rabbit Pierce 1:100,000 Goat IgG 
Anti Rat Stressgen 1:10,000 Rabbit IgG 
Anti Goat Pierce 1:100,000 Rabbit IgG 
Anti Mouse Pierce 1:100,000 Goat IgG 
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3.3.3 Microarray Profiling and Validation  
3.3.3.1 Expression Microarray Profiling 
Human HT-12 v4 Expression BeadChip Kit (Illumina, BD-103-0204) containing 47,231 
oligonucleotide probes was employed to profile the differential gene expression between control 
and 17-AAG treated HuH-7 cells. RNA was isolated using RNeasy® Mini Kit (Qiagen) according to the 
manufacturer’s instructions. Subsequent cDNA generation, probe labeling and array hybridization 
were performed by Duke-NUS Genome Biology Facility, Singapore. Partek® Genomics Suite™ was 
used to analyze differential gene expression profiles in the control and treated cells. Significantly 
deregulated genes were identified based on the following criteria: (i) fold change more than 1.5 
(significantly upregulated) or less than -1.5 (significantly downregulated) and (ii) p-value less than or 
equal to 0.05.  
3.3.3.2 Protein Microarray Profiling 
Kinex™ KAM-850 Antibody Microarray service (Kinexus Bioinformatics Corporation) was 
engaged to profile differential protein expression between control and 17-AAG treated HuH-7 and 
Hsp90 siRNA treated HuH-7 cells. The KAM-850 Antibody Microarray consists of 510 pan-specific and 
340 phosphosite-specific antibodies, providing unique detection of 189 unique protein kinases, 31 
protein phosphatases, 142 regulatory subunits of these enzymes and cell signaling proteins and 
further track non-redundant phosphorylation of 128 sites in protein kinases, 4 sites in protein 
phosphatases and 155 sites in other cell signaling proteins. Cell pellets were lysed with 100 µl lysis 
buffer (20 mM MOPS pH 7.0, 2 mM EGTA, 5 mM EDTA, 20 mM sodium pyrophosphate, 1 mM 
sodium orthovanadate, 1% Igepal CA-630, 1 mM dithiothreitol, 1 X Roche Complete Protease 
Inhibitor Cocktail). The lysate was incubated on a rotating platform for 10 min at 4˚C and 
subsequently, sonicated using a Bioruptor® (Diagenode Denville) for 10 min at high setting, 30 sec 
‘on’ followed by 30 sec ‘off’. Cell debris was removed by centrifugation at 13,000 rpm for 30 min at 4 
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ºC and cell lysates were transferred to new tubes. 50 μg of lysate protein were used to perform the 
Kinex™ analyses. 
3.4 In Silico Functional and Pathways Analyses 
In Silico Functional and Pathways analyses were performed using Ingenuity Pathways 
Analysis (IPA, Ingenuity Systems; www.ingenuity.com). The identified deregulated genes by 17-AAG 
were uploaded into IPA. Core analysis was used to interpret the uploaded gene list. The programme 
uses right-tailed Fisher Exact Test to calculate the p-value. It take account the number of analyzing 
genes involving in that function/pathway and the total number of molecules that are related with 
that function in Ingenuity Knowledge Base.  The lower the p-value indicated a higher level of over-
representation of genes involved in the corresponding function/pathway.  
3.5 Statistical analysis of experimental data 
Experimental data presented in this thesis were obtained from at least three independent 
experiments, unless otherwise stated. Data were expressed as mean values of experimental 
triplicates ± standard error (SE). Student’s two-sided unpaired t test was performed to analyze for 
statistical significance of differences between sample means. For transcript expression analysis in 
tumour and paired non-tumourous tissues of HCC patients, data were expressed as median values ± 
SE. Student’s two-sided unpaired t test was performed to analyze for statistical significance of 
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Chapter 4: Cellular Effects of Hsp90 Inhibition 
4.1 Introduction  
Targeting Hsp90 has emerged as a promising strategy for therapeutic intervention in HCC 
(Breinig et al., 2009). Hsp90 chaperones many oncoproteins that drive cancer malignancy (Figure 
2.1) (Trepel et al., 2010). The reduction of Hsp90’s activity would thus have detrimental 
consequences toward the survival and development of cancer cells. Hence, it is envisaged that by 
elucidating the anti-cancer activities of Hsp90 inhibitors, a better understanding on the precise 
influence of Hsp90 on HCC would be achieved. At the same time, the inhibitors’ effectiveness in 
targeting HCC could be evaluated. Among the list of proteins chaperoned by Hsp90, many of them 
are signaling molecules that are involved in cell growth and survival (Taipale et al., 2010). Thus, this 
suggests that Hsp90 has a crucial role in promoting tumour growth by supporting proliferative or 
anti-apoptotic mechanisms. Indeed, Hsp90 inhibitors were found to reduce cell growth and induce 
cell death in many cancers such as breast and ovarian (Banerji et al., 2005; Basso et al., 2002). In 
HCC, studies using different Hsp90 inhibitors had shown to reduce cell viability and induce cell death 
(Breinig et al., 2009; Watanabe et al., 2009). However, these studies carried out on HCC have thus 
far used derivates of geldanamycin such as 17-AAG to inhibit the activity of Hsp90. This group of 
Hsp90 inhibitors possesses a quinone group in their chemical structure which is likely to cause 
cellular cytotoxicity (Solit and Chiosis, 2008). Therefore, this sparks the interest of this study to 
employ a chemically distinct Hsp90 inhibitor, radicicol, which does not possess the quinone group, to 
examine the authenticity of the cellular effects of Hsp90 inhibition in HCC cells.  
For this investigation, the well-differentiated hepatocytes, HepG2 and Huh-7 cells, were 
treated with either 17-AAG or radicicol and subsequently, their rate of proliferation and apoptosis 
profile were examined. In addition, the influence of these Hsp90 inhibitors on the apoptotic pathway 
was further investigated through determining the activities of various caspases. Characterization of 
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the apoptotic pathway induced by Hsp90 inhibitor treatment could potentially shed light on how 
Hsp90 might be involved in mediating cell death. Furthermore, the effects of Hsp90 inhibition on cell 
mobility would also be examined, as HCC is known to transform and metastasize (Aravalli et al., 
2013). Finally, characterization of the cellular effects induced by Hsp90 inhibition helps to pave the 
way for subsequent studies to determine the molecular changes that result in such effects observed 
in HCC cells treated with Hsp90 inhibitor. 
 
4.2 17-AAG and Radicicol Selectively Caused a Cytotoxic Effect in HepG2 and Huh-7 cells 
Hsp90 inhibitors are known to be selective in targeting cancer cells. They had shown to 
exhibit activities against numerous types of cancer cells at a much lower half maximal inhibitory 
concentration (IC50) as compared to the non-tumourigenic cells (Kamal et al., 2003). As such, to 
evaluate if the two Hsp90 inhibitors, 17-AAG and radicicol, would also be able to selectively target 
HCC cells and not the non-tumourigenic liver cells, IC50 of 17-AAG and radicicol on the viability of 
HepG2, Huh-7 and NehepLXTH cells were determined and compared. HepG2 and Huh7 cells are 
well-differentiated hepatocyte-derived cellular carcinoma cell lines whereas NehepLXTH are hTERT 
immortalized hepatocyte epithelial cells and share the phenotypic characteristics of non-
tumourigenic adult liver epithelial cells.  
The WST-1 assay was employed to assess cell viability. WST-1 is a form of tetrazolium salt 
that would be cleaved into insoluble formazan dye by cellular mitochondrial dehydrogenases 
present in viable cells. Based on the intensity of the formazan dye, the number of viable cells can 
then be extrapolated and determined. Approximately 3 x 103 cells were seeded into a 96-well plate 
for 24 hrs. Following which, various doses of 17-AAG and radicicol were added to each well and 
incubated for 48 hrs. Subsequently, the cells were incubated with WST-1 reagent for an hr and the 
number of viable cells relative to the untreated control group was determined.  
Chapter 4 Cellular Effects of Hsp90 Inhibition 
64 
 
The results showed a dose-dependent decrease in cell viability by 17-AAG and radicicol in 
both HepG2 and Huh-7 cells (Figure 4.1). The IC50 values of 17-AAG for 48 hrs, calculated from three 
independent experiments, were 0.10 μM and 0.04 μM for Huh-7 and HepG2 cells respectively. As for 
radicicol, it exhibited an IC50 of 0.08 μM and 0.07 μM on Huh-7 and HepG2 cells respectively. Both 
the IC50 of the 17-AAG and radicicol against the Huh-7 and HepG2 cells were in the nanomolar 
concentration. This indicated a high efficacy for both the inhibitors in targeting HCC cells. On the 
other hand, NehepLXTH cells were significantly less sensitive towards 17-AAG and radicicol 
treatment. The IC50 of 17-AAG on NehepLXTH cells was approximately 10 μM while that of radicicol 
was beyond the tested concentrations (Figure 4.2). The lack of efficacy of Hsp90 inhibitors on 
NehepLXTH cells while exerting a nanomolar concentration of IC50 against HCC cell lines supported 
the notion that Hsp90 inhibitors selectivity target cancer cells. In the subsequent experiments, 
standardized concentrations of 0.10 μM (IC50 of 17-AAG against Huh-7) and 1 μM (10 times IC50 of 
17-AAG against Huh-7) were used for both the Hsp90 inhibitors unless otherwise stated.   
   
 






































 Figure 4.1: HCC Cell Vability Test. HepG2 and Huh-7 cells were treated with increasing concentration of 17-AAG or 
radicicol. Cell viability was analyzed using WST-1 assay after 48 hours of treatment with the respective Hsp90 inhibitors. 
Results shown were representative of three independent experiments. The IC50 of 17-AAG were 0.10 μM and 0.04 μM 
for Huh-7 and HepG2 cells respectively. As for radicicol, its IC50 were 0.08 μM (Huh-7), 0.07 μM (HepG2) for Huh-7 and 
HepG2 cells respectively. 
Huh-7 cells Huh-7 cells 
























0 0.025 0.05 0.075 0.1 0.5 1 10
17-AAG Concentration [μM] 
17-AAG Concentration [μM] Radicicol Concentration [μM] 
Radicicol Concentration [μM] 
HepG2  cells HepG2  cells 






















0 0.025 0.05 0.075 0.1 0.5 1 10
Figure 4.2: Non-tumourigenic Liver Cell Vability Test. NehepLXTH cells were treated with increasing concentration of 
17-AAG or radicicol. Cell viability was analyzed using WST-1 assay after 48 hours of treatment with the respective Hsp90 
inhibitors. Results shown were representative of three independent experiments. The IC50 of 17-AAG were 10 μM 
whereas the IC50 of radicicol is beyond the tested concentration.  
NehepLXTH cells NehepLXTH cells 
17-AAG Concentration [μM] Radicicol Concentration [μM] 
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4.3 Hsp90 Inhibition Selectively Arrested the Growth of HepG2 and Huh-7 cells 
 Hsp90 client proteins such as Raf-1, p38, Erk5 are key regulators that promote cell 
proliferation and development. Hence, degradation of these proteins as a result of inhibiting Hsp90’s 
activity could potentially lead to a reduction in cell growth. Studies prior to this project had reported 
that treatment with geldanamycin derivatives decreased cell proliferation in HCC cell lines (Breinig et 
al., 2009; Watanabe et al., 2009). To ascertain that this outcome was attributed to the inhibition of 
Hsp90 and not due to “off-target” effects of the inhibitor used, a chemically distinct Hsp90 inhibitor, 
radicicol, was used in parallel with 17-AAG to treat the cells in this study. Approximately 3 x 103 
HepG2 or Huh-7 cells were seeded in a 96-well plate and incubated overnight. Subsequently, 0.1 μM 
or 1 μM of the respective Hsp90 inhibitors was added to the individual well. Analysis of cell growth 
was then carried out using a live cell imagery system where 4 fixed field images were taken from 
each individual well at a 2 hr interval for a period of 2 days. From these images, the rate of growth 
for each treatment group was calculated based on the increase in cell confluency relative to time 0 
hr.   
As presented in Figure 4.3, the growth of both Huh-7 and HepG2 cells was reduced when 
treated with either 17-AAG or radicicol. At the 24th hour, 0.1 μM and 1 μM of 17-AAG were able to 
reduce the growth of Huh-7 cells by 26% and 31% respectively as compared to the DMSO treated 
cells (Figure 4.4). At the end of 48 hrs treatment with 0.1 μM and 1 μM of 17-AAG, cell growth was 
reduced by 38% and 47% respectively. Treatment with radicicol was also found to arrest the growth 
of Huh-7 cells. Treatment with 0.1 μM and 1 μM of radicicol after 24 hrs decreased the growth of the 
cells by 21% and 37% respectively. After 48 hrs of treatment, cell growth was decreased by 28% and 
51% respectively. Besides Huh-7 cells, both Hsp90 inhibitors were also able to inhibit the growth of 
HepG2 cells. Proliferation of HepG2 cells decreased by 34% and 44% when cells were incubated with 
0.1 μM and 1 μM of 17-AAG respectively for 48 hrs. Similarly, 0.1 μM and 1 μM of radicicol reduced 
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the growth of HepG2 cells by 48% and 54% respectively after 48 hrs. The results showed that there is 
no significant difference in the efficacy between the two Hsp90 inhibitors and the cell lines used.  
Interestingly, analysis of the morphology of the cells revealed that a higher proportion of 
cells treated with Hsp90 inhibitors retained a “round” morphology as compared to the DMSO 
treated cells (Figure 4.5). Cell rounding is a common feature indicating that a cell is undergoing 
mitosis (Thery and Bornens, 2008). Examination of the cell division process in HepG2 and Huh-7 cells 
revealed that cells would become round before dividing into two daughter cells (Figure 4.6). From 
time-lapse images, cells treated with Hsp90 inhibitors were arrested at the “round” phenotype 
whereas, in the control group, those cells with the round phenotype proceeded with cell division 
(Figure 4.7 & Figure 4.8). This suggested that Hsp90 inhibitors had induced mitotic arrest of cell cycle 
in the HCC cells. 
In contrast, Hsp90 inhibitors were not able to inhibit the growth of NehepLXTH cells. There 
was no significance difference in the relative cell confluency between Hsp90 inhibitors treatment 
and the DMSO treated control cells at both the 24th and the 48th time point (Figure 4.9). These 
results demonstrated that both the Hsp90 inhibitors, 17-AAG and radicicol, were able to selectively 
target HCC cells and remain ineffective in inhibiting non-tumourigenic liver cells. 
 


















 Figure 4.3: Growth Profile of HepG2 and Huh-7 Cells over 48 hours Following the Treatment with Hsp90 Inhibitors. Cell confluency 
was monitored at every 2 hr interval over a period of 48 hours. The cell confluency at every interval was normalized with the initial 
cell confluency at time 0. The growth profile showed that Hsp90 inhibitors, 17-AAG and radicicol (RAD), would independently inhibit 
the cells to proliferate slower as compared to the control cell (DMSO) in both of the cell lines. 
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Figure 4.4: Confluency of HepG2 and Huh-7 Cells at 24 and 48 hours Following the Treatment with Hsp90 Inhibitors. Cells were treated 
with 0.1 μM and 1 μM of Hsp90 inhibitors, 17-AAG and radicicol (RAD). Results shown were representative of three independent 
experiments. There were significant reductions in the cell confluency when cells were treated with Hsp90 inhibitors in comparison to cells 
treated with vehicle control (DMSO) at 24 and 48 hours for both cell lines. Statistical test was carried out to compare each individual 
treatment group against the control group (DMSO) of the same particular time point indicated. (* Denoted p-value < 0.05, ** denoted p-
value < 0.01 and *** denoted p-value < 0.001) 
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Figure 4.5: Morphology of HepG2 and Huh-7 Cells Upon Treatment with Hsp90 Inhibitors. Upper panel represents images of 
HepG2 cells whereas the lower panel represents images of Huh-7 cells. Cells were treated with either 1 μM of 17-AAG or 
radicicol (RAD) and were compared with the control group treated with the vehicle control, DMSO. The images were taken at 
the 24th hour time point. The images revealed that HepG2 cells treated with both Hsp90 inhibitors had a higher proportion of 
cells with “round” morphology as compared to those treated with DMSO in the control experiment. Similarly, when treated 
with Hsp90 inhibitors, there is a higher proportion of Huh-7 cells with “round” morphology as compared to the DMSO treated 
group.     
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Figure 4.6: Time-lapse Images of wild-type HepG2 and Huh-7 Cells. Images at the upper panel represents wild-type HepG2 cells 
whereas images of the lower panel represents wild-type Huh-7 cells. Cell rounding is a common feature of cells undergoing 
mitosis. The time-lapse images capturing the wild-type HepG2 and Huh-7 cells revealed that the parent cell will adopt a “round” 
morphology (indicated by the white arrow) during mitosis and subsequently divide to become two daughter cells. 
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Figure 4.7: Time-lapse Images of HepG2 Cells Treated with Hsp90 Inhibitors. HepG2 cells were treated with either 17-AAG or 
radicicol (RAD).The time-lapse images revealed that when treated with radicicol or 17-AAG, many of the HepG2 cells (indicated 
by the white arrow) were arrested at the “round” morphology and did not proceed with cell division. In contrast, cells treated 
with DMSO (indicated by the yellow arrow) underwent cell rounding and subsequently proceeded with cell division to produce 




















Figure 4.8: Time-lapse Images of Huh-7 Cells Treated with Hsp90 Inhibitors. Huh-7 cells were exposed to either 17-AAG or 
radicicol (RAD) and compared with DMSO treated cells. The time-lapse images revealed that when treated with radicicol or 17-
AAG, a number of Huh-7 cells (indicated by the white arrow) were arrested at the “round” morphology and did not proceed 
with cell division. In contrast, cells treated with DMSO (indicated by the yellow arrow) underwent cell rounding and 
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Figure 4.9: Confluency of NehepLXTH Cells Treated with Hsp90 Inhibitors at 24 and 48 hours. NehepLXTH cells were treated 
with 0.1 μM and 1 μM of Hsp90 inhibitors, 17-AAG and radicicol (RAD). Results shown were representative of three 
independent experiments. There is no significant decrease in the cell confluency when cells were treated with Hsp90 inhibitors 
in comparison to cells treated with vehicle control (DMSO) at 24 and 48 hours. 
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4.4 Hsp90 Inhibitors Induced Apoptosis in HepG2 and Huh-7 cells 
Besides regulating signaling proteins that are involved in cell growth, Hsp90 also chaperones 
proteins such as Bcl-2, Bcl-xl and Bid, which mediate the apoptosis process (Nimmanapalli et al., 
2003). When Hsp90 function is compromised, it will lead to the degradation of anti-apoptotic Bcl-2 
and Bcl-xl while enhancing the cleavage of pro-apoptotic Bid to activate the apoptosis pathway (Dias 
et al., 2002; Nimmanapalli et al., 2003; Zhao and Wang, 2004). Hence, this ignites the interest of this 
study to investigate if the reduction in cell proliferation by the Hsp90 inhibitors could be attributed 
to an increase in number of cell death. Flow cytometry analysis using annexin V-PE and 7AAD 
fluorescein label was employed to profile the number of apoptotic cells. When cells are undergoing 
apoptosis, the integrity of the plasma membrane is compromised and leads to the exposure of 
phosphatidylserine on the extracellular surface. This allows annexin V to bind to phosphatidylserine 
and consequently, enables the cells undergoing apoptosis to be labelled. The 7AAD allows viable 
cells to be differentiated from the non-viable cells as the nucleus integrity of the non-viable cell is 
disrupted and would allow 7AAD to penetrate and intercalate with the DNA inside the nucleus. Early 
apoptotic cells will be profiled as annexin V positive and 7AAD negative whereas late 
apoptotic/necrotic cells would be stained positive for both annexin V and 7AAD. For this 
investigation, 5 x 105 cells were seeded in 6-well plates for 12 hrs. Afterwhich, the Hsp90 inhibitor, 
17-AAG or radicicol, was added to the cells at various concentrations and incubated for 48 hrs. 
Subsequently, the adherent and floating cells were both harvested and stained with annexin V and 
7AAD before being analyzed by flow cytometry.  
The assay revealed that both 17-AAG and radicicol induced apoptosis in Huh-7 cells in a 
dose-dependent manner (Figure 4.10). An increased concentration of the Hsp90 inhibitors treatment 
was able to induce a greater number of early apoptotic cells. Nevertheless, significant differences in 
the number of early apoptotic cells were only observed when 1 μM or higher concentration of 17-
AAG were used (Figure 4.10). Although similar trend was also observed with radicicol, no significant 
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differences were found when compared to cells treated with the vehicle control, DMSO. Treatment 
with 1 μM of 17-AAG also induced statistically significant differences in HepG2 (Figure 4.11). 
However, the magnitude of the cell death caused by Hsp90 inhibitors was lower in HepG2 as 
compared to Huh-7. Interestingly, 17-AAG and radicicol were not able to induce a much higher 






Figure 4.10: Apoptosis Profile of Huh-7 Cells Treated with Hsp90 Inhibitors. Huh-7 cells 
were treated with increasing concentration of either 17-AAG or radicicol. The values 
indicated the average percentage of apoptotic cells taken from three independent 
experiments. Both 17-AAG and radicicol independently induced apoptosis in Huh-7 cells in a 
dose-dependent manner where increase concentration of the Hsp90 inhibitors caused an 
increased proportion of cell to undergo early apoptosis. 1 μM and above of 17-AAG was 
able to induce significant increase in cell death in Huh-7 cells. (** denoted p-value < 0.01) 
























Figure 4.11: Apoptosis Profile of HepG2 Cells Treated with Hsp90 Inhibitors. HepG2 cells 
were treated 0.1 μM and 1 μM of either 17-AAG or radicicol (RAD). The values indicated 
the average percentage of apoptotic cells taken from three independent experiments. 1 
μM of 17-AAG was able to induce significant increase in cell death in HepG2 cells. (** 
denoted p-value < 0.01) 
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4.5 Apoptosis Induced by Hsp90 Inhibitor, 17-AAG, was Mediated Via Caspases  
Activation of cysteine-aspartic proteases (caspases) is a key event required for the induction 
of apoptosis. Pro-caspases would be cleaved via proteolysis to be activated in order to orchestrate 
the apoptotic process. To validate the induction of apoptosis by 17-AAG treatment in Huh-7, the 
activation of caspase 3, a critical executioner in the apoptosis pathway, was assayed using caspase 3-
specific fluorometric substrate Ac-DEVD-AFC.  
The results obtained showed a significant increase in the activity of caspase 3 when the cells 
were treated with 17-AAG (Figure 4.12). The level of caspase activity also correlated with the 
concentration of 17-AAG used.  In addition, caspase 6, which is a downstream effector of caspase 3 
(Slee et al., 2001), also exhibited an elevated level of activity. The results demonstrated that 17-AAG 
was able to induce caspase-dependent cell death.  
In order to rule out the possibility that the quinone moiety of 17-AAG is responsible for the 
induction of caspase 3 activity, Hsp90 siRNA was also used to abrogate the activity of Hsp90. 
Although reduced level of Hsp90 did not induce a similar increase in caspase 3 activity as compared 
to the 17-AAG treated cells, the Hsp90 siRNA treatment was able to induce a decrease in caspase 3 
activity that is of statistical significant in comparison with control cells treated with scrambled siRNA 
(Figure 4.13). This result was further supported by a similar observation on caspase 6 activity. Taken 
together, the data showed that Hsp90 inhibition induced apoptosis in HCC cells. Nevertheless, it is 
important to note that other mechanisms independent of caspase may also contribute to the 
induced cell death observed.  
 
4.6 Hsp90 Inhibitor, 17-AAG, Induced Apoptosis via Intrinsic Pathway 
Apoptosis can be activated through the intrinsic and/or extrinsic pathway. Each of them is 
initiated under different circumstances. The ability to elucidate the pathway(s) induced by 17-AAG 
would potentially provide insight into the effects of Hsp90 inhibition on cell death function in HCC. 
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Extrinsic apoptotic pathway is characterized by the formation of death inducing signaling complex 
and consequently leads to the activation of caspase 8. On the other hand, the intrinsic apoptotic 
pathway involved the release of cytochrome C following the permeabilisation of mitochondria, 
which lead to the activation of caspase 9. To characterize the apoptotic pathway initiated by 17-
AAG, activities of caspase 8 and 9 were thus determined.  
The caspase assay revealed that 17-AAG led to an increase in caspase 9 activity whereas 
there was no significant difference in the caspase 8 activity as compared with the cells treated with 
DMSO (Figure 4.12). When treated with 0.1 μM of 17-AAG, the caspase 9 activity in the Huh-7 cells 
was increased by 3.07 times as compared to the control. A greater magnitude of the caspase 9 
activity was observed when cells were treated at a higher concentration of 17-AAG. The activity of 
caspase 9 was 6.59 times as compared to the control. The results revealed that the apoptosis 











Figure 4.12: Capase Activity in 17-AAG Treated Huh-7 Cells. Caspase activity was assayed using the 
caspase-specific fluorometric substrate (Table 3.1). Treatment with 17-AAG for 48 hours increased 
the activities of caspase 3 and 6 significantly as compared to the control group. Caspase 9 activity 
was also significantly increased but there was no significant differences in the caspase 8 activity as 
compared to cell treated with DMSO. (* denoted p-value < 0.05, ** denoted p-value < 0.01) 
 
















Figure 4.13: Capase Activity in Hsp90 siRNA Treated Huh-7 Cells. A) Hsp90 siRNA was used to 
deplete the protein level of Hsp90. siRNA was able to induce statistical significant decrease in 
the activities of caspase 3, caspase 6 and caspase 9 in comparison with control cells treated with 
scrambled siRNA. However, there is no increase in caspase 8 activity. (* denoted p-value < 0.05) 
B) Hsp90 siRNA reduced the protein expression of Hsp90 as compared to the scrambled siRNA 
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4.7 Hsp90 Inhibitors Reduced Cell Motility  
Metastasis is a one of the hallmarks of cancer (Hanahan and Weinberg, 2011).  The motility 
of cancer cells has been well documented to play a crucial role in the metastasis process. A high 
incidence of metastasis has been reported in HCC patients (Bosch et al., 2004).  Given that cell 
motility is a key factor in regulating metastasis, the effect of Hsp90 inhibitors on cell mobility was 
examined in HepG2 and Huh-7 cells through wound-healing assay. Wound-healing assay allows the 
study of the rate of cell migration in vitro. In this assay, a gap, which is known as the wound, is 
created on a monolayer of cells.  The wound was monitored at every 2 hr interval for a period of 60 
hrs. The rate of cell migration was determined by the extent of wound closure. 
The results showed that cell migration at the edge of exposed regions was slower in cells 
treated with either radicicol or 17-AAG when compared to the cells treated with vehicle control, 
DMSO (Figure 4.14, Figure 4.15). HepG2 and Huh-7 cells incubated with DMSO were able to close 
the wound in 60 hrs. In comparison, the presence of 0.1 µM 17-AAG reduced the migration rate in 
HepG2 and Huh-7 cells by approximately 38% and 47% respectively (Figure 4.16). Similarly, 
treatment with 0.1 µM of radicicol decreased the migration rate of HepG2 and Huh-7 by 
approximately 12%. In the presence of 1 µM of 17-AAG and radicicol, migration rate of Huh-7 was 
reduced by 60% and 68% respectively. The migration rate of HepG2 was also reduced by 53% and 
36% when the cells were treated with 1 µM of 17-AAG and radicicol respectively. The results thus 































Figure 4.14: Wound-Healing Assay Conducted using HepG2 and Huh-7 Cells. HepG2 and Huh-7 
cells were treated with either 1 μM of 17-AAG or radicicol (RAD) and compared with DMSO treated 
cells. A wound (decipted by the white line) was created on a monolayer of cells. HepG2 and Huh-7 
cells treated with DMSO were able to close the wound over a 60-hours period. However, in the 
presence of 17-AAG or radicicol, the cell motility in the two HCC cell lines were impaired, which 
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Figure 4.15: The Profile of the Wound Gap for HepG2 and Huh-7 Cells Over 48 hour Period. Wound width was monitored at a 2 
hr interval over a period of 48 hours.  Relative wound width was calculated by comparing the wound width with the initial gap of 
the wound (0 hour) of each individual treatment. The relative wound width profile showed that in the presence of 17-AAG or 
radicicol (RAD), the Huh-7 cells exhibited a slower rate of wound closing as compared to the DMSO treated cells. Similarly, the 
migratory abilities of HepG2 cells were affected by the presence of 17-AAG and radicicol.  
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Figure 4.16: Relative Wound Width at 24 and 48 hour Time Point. The relative wound 
width was calculated by comparing the wound width with the initial gap of the wound (0 
hour) of each individual treatment. When HepG2 and Huh-7 cells were treated with 
either 17-AAG or radicicol (RAD), the closure of the wound gap were slower as compared 
to the DMSO treated cells. This indicated that HepG2 and Huh-7 cells migrated slower in 
the presence of the Hsp90 inhibitors as compared to the DMSO treated cells. (* denoted 
p-value < 0.05, ** denoted p-value < 0.01). 
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A great attention has been paid to Hsp90 inhibitors as they emerged to be promising drugs 
that exploited the achilles heel of cancers (Taipale et al., 2010). While cancer cells evolved to 
proliferate uncontrollably and gain immunity against apoptosis, they also consequently developed 
greater dependence on the Hsp90 chaperone function (Whitesell et al., 2005). A study had 
previously revealed that Hsp90 inhibitor exhibited a higher affinity for tumour cells as compared to 
the non-transformed cells (Kamal et al., 2003). Moreover, xenograft studies with breast, ovarian and 
many other cancers showed that Hsp90 inhibition can arrest the growth of tumour (Banerji et al., 
2005; Basso et al., 2002; Burger et al., 2004). This gives rise to the possibility of using Hsp90 
inhibitors as a therapeutic intervention for HCC treatment. Therefore, this ignites the interest of this 
study to investigate the Hsp90 inhibitors’ cellular activity against HCC cell lines and determine if the 
inhibitors would selectivity target the HCC cells but not towards non-tumourigenic cells. 
The IC50 of 17-AAG and radicicol in two HCC cell lines, HepG2 and Huh-7, were first 
determined to select the appropriate dose to be used in subsequent experiments. Both the 
inhibitors shared similar efficacies against the two cell lines. Moreover, the IC50 determined in this 
study against HepG2 and Huh-7 cells for the two Hsp90 inhibitors, 17-AAG and radicicol, were 
comparable with that reported in other studies which were also in the nanomolar range (Breinig et 
al., 2009). Consistent with previous findings, both Hsp90 inhibitors selectively target HCC cells but 
not the non-transformed cells. The IC50 of 17-AAG on NehepLXTH cells was 10 μM which is 100 times 
greater than the IC50 of 17-AAG on Huh-7 cell. Furthermore, radicicol did not have an inhibitory 
effect on the NehepLXTH cells’ viability even at the maximum tested concentration of 10 μM.  
Next, the study examined the effect of Hsp90 inhibitors on cell proliferation. Numerous 
Hsp90 clients proteins are key regulators of cell growth and development and therefore, the 
disruption of Hsp90’s activity would likely affect cell survival. In line with this notion, the results 
showed that 17-AAG and radicicol reduced cell proliferation by more than 50% relative to the DMSO 
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treated cells after 48 hrs of drug treatment. With the two inhibitors possessing different chemical 
structure, the observed effect on cell proliferation by the inhibitors was therefore unlikely to be an 
“off target” event. Interestingly, a higher proportion of cells displayed a rounded morphology when 
treated with both the Hsp90 inhibitors. Cell rounding is a common feature of cells undergoing cell 
division (Thery and Bornens, 2008). The time-lapse images capturing the wild-type cells revealed 
that these rounded cells indeed underwent cell division. However, the addition of Hsp90 inhibitors 
stalled this process, causing the cells to remain in the rounded morphology. Numerous studies had 
shown that inhibition of Hsp90 caused cell cycle arrest, though at various phases in different cell 
lines (Bedin et al., 2004; Senju et al., 2006; Watanabe et al., 2009). This strongly suggested that the 
Hsp90 inhibitors induced cell cycle arrest on HepG2 and Huh7 cells, leading to a reduction in cell 
proliferation. In addition, this study had shown that the two Hsp90 inhibitors were only effective in 
targeting the growth of HCC cells but not the non-transformed NehepLXTH cells. 
The two Hsp90 inhibitors’ ability to induce apoptosis was subsequently examined in the two 
HCC cell lines. The apoptosis assay revealed that Hsp90 inhibitors were able to induce apoptosis in a 
dose dependent manner. At 10 times the IC50 concentration, 17-AAG was able to induce a significant 
amount of cell death as compared to the DMSO treated cells. Surprisingly, both the Hsp90 inhibitors 
were not able to induce a greater cell death as of expected.  Hsp90 is known to negatively regulate a 
number of pro-apoptotic complexes such as apoptosis protease activating factor and BAD while 
supports the activation of anti-apoptotic proteins such as Bcl-XL and Bcl-2 (Dias et al., 2002; 
Nimmanapalli et al., 2003; Rodina et al., 2007; Zhao and Wang, 2004). Therefore, the inhibition of 
Hsp90 would likely to result in cell death. However, the data revealed that 1 μM of 17-AAG induced 
early apoptosis in 12.3% of the treated Huh-7 cells whereas 1 μM of radicicol could only induced cell 
death in 2.3% of the treated Huh-7 cells. Importantly, the live cell imaging also revealed that there is 
a low level of cells undergoing apoptosis. Taken together, both the Hsp90 inhibitors, 17-AAG and 
radicicol, reduced cell proliferation predominantly through its cytostatic effect coupled with 
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induction of apoptosis at a smaller extent. Although Hsp90 inhibitors were not able to result in 
extensive cell death, the cytostatic effect of the inhibitors remains an attractive property as liver 
cancers were characterized by hyperproliferation at the early stages of chronic inflammation (Farazi 
and DePinho, 2006).  
The lower than expected cell death induced by the two Hsp90 inhibitors could be due to an 
increase level of Hsp70 via activation of Hsf1. In vitro and in vivo studies had shown that Hsp70 was 
upregulated through Hsf1 activation when Hsp90 function was comprised (Maloney et al., 2007; 
Maloney et al., 2003; Whitesell et al., 2003). Hsf1 is a constitutively expressed transcription factor 
which lies dormant by binding to Hsp90 (Ali et al., 1998; Zou et al., 1998). Upon the inhibition of 
Hsp90, Hsf1 is released and undergoes trimerization to become activated. The activation of Hsf1 
induces the overexpression of Hsp70. Hsp70 had been reported to inhibit apoptosis by binding 
apoptosis protease activating factor-1 thereby preventing the formation of the apoptosome 
complex, consisting Apaf-1, cytochrome c and caspase 9 (Saleh et al., 2000). As shown in this study, 
17-AAG induced apoptosis through the activation of caspase 9 and not caspase 8. Hence, it might 
have suppressed the magnitude of apoptosis induced by the two Hsp90 inhibitors in HCC. 
Apoptosis induced by 17-AAG observed in Huh-7 was initiated via the intrinsic pathway 
mediated by caspase 9. Caspase 9 was shown have higher protease activity in the presence of the 
17-AAG compared to control treatment. On the other hand, no different in the activity of caspase 8 
was observed with 17-AAG treatment. These results differed from other studies that focused on cell 
lines such as bladder and melanoma where treatment with Hsp90 inhibitors such as 17-AAG induced 
both the intrinsic and extrinsic apoptotic pathways (Georgakis et al., 2006; Karkoulis et al., 2010; Liu 
et al., 2012). The discrepancy is likely to be due to the different molecular makeup of the cell lines. 
HCC cell lines including Huh-7 had been reported to be resistant to apoptosis induced via extrinsic 
pathway (Yamanaka et al., 2000). TNF-related apoptosis-inducing ligand (TRAIL), capable of inducing 
Chapter 4 Cellular Effects of Hsp90 Inhibition 
89 
 
apoptosis via the extrinsic pathway, was similarly tested to have its death signal inhibited at the 
caspase 8 level in the HCC cell lines.  
Instead, the apoptosis induced by Hsp90 inhibitors in Huh-7 cells is likely to be mediated 
through the B-cell lymphoma–2 (Bcl-2) family of proteins that regulate the intrinsic pathway of 
apoptosis. Bcl-2 family consists of two groups that are either pro-apoptotic (e.g. BAD and Bim) or 
anti-apoptotic (e.g. Bcl-2 and Bcl-xl). The initiation of apoptosis is dependent on the balance of these 
two groups of proteins. Hsp90 inhibitors are able to tilt the balance towards apoptosis through 
affecting the activities of some members of the Bcl-2 family. Inhibition of Hsp90 is known to degrade 
Akt, a key mediator of PI3K/Akt/mTOR pathway, and subsequently lead to the activation of pro-
apoptotic BAD (Rodina et al., 2007). In addition, Hsp90 chaperones the anti-apoptotic Bcl-2 protein 
and with the function of the chaperone compromised, the functionality of Bcl-2 is likely to be 
affected, resulting in increased apoptosis. One study had shown that Bcl-2 overexpression negates 
the apoptosis induced by 17-AAG (Nimmanapalli et al., 2003).  
Finally, the effect of the two Hsp90 inhibitors on cell motility was examined. Using the 
wound-healing assay, both the Hsp90 inhibitors were able to prevent the cells from closing the gap. 
One of the key factors in mediating cell motility is the proto-oncogenic cellular-MET (c-Met) (Ma et 
al., 2003). c-Met had been reported to be overexpressed in HCC, supporting cell migration and 
invasion of the cells. Importantly, Hsp90 inhibitors have demonstrated to abrogate the c-Met 
signaling (Goyal et al., 2013). Besides c-Met, type 1 insulin-like growth factor receptor (IGF-1R) was 
also implicated in cell motility (Nussbaum et al., 2008). Overexpression of IGF-1R was shown to 
promote cell migration and inhibition of the IGF-1R expression using siRNA was able to reverse the 
trend (Yuen et al., 2007). Hsp90 inhibitors reduced the IGF-1R expression at both the transcriptional 
and protein levels, consequently resulted in reduced cell motility in pancreatic cancer cells. (Lang et 
al., 2007).  
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In summary, this chapter showed that both Hsp90 inhibitors, 17-AAG and radicicol, were 
able to reduce the proliferation of HepG2 and Huh-7 cells largely through the arrest of cell cycle. In 
addition, the inhibitors induced cell death on both cells lines via an intrinsic pathway. Furthermore, 
the motility of cells was also affected in the presence of Hsp90 inhibitors.  By using two chemically 
distinct inhibitors, the study further supports that the cellular effects observed were likely due to the 
inhibition of Hsp90 functions rather than “off target” effects of the inhibitors. With the 
characterization of the cellular effects of Hsp90 inhibition, the study subsequently proceeded to 
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Chapter 5: Molecular Basis of Hsp90 Inhibition 
5.1 Introduction 
Elucidating the molecular events deregulated following treatment with Hsp90 inhibitors 
remains one of the major challenges in the development of Hsp90-targeted therapy. Currently, 
predicting the effectiveness of Hsp90 inhibitors on a particular cancer is based on whether certain 
key oncoproteins that are important for cancer survival would be depleted upon exposure to the 
inhibitor (Travers et al., 2012). However, recent results from the concluded clinical trials revealed 
that such an approach was insufficient to determine the efficacy of Hsp90 inhibitor in the clinical 
setting (Neckers and Workman, 2012). It suggested that other oncoproteins that were not targeted 
by Hsp90 inhibitors could still continue and drive cancer malignancy. Furthermore, the inherent 
ability of cancer cells to evolve and trigger protective mechanism in response to the exposure to 
Hsp90 inhibitor could neutralize the detrimental effects of the inhibitor. In addition, the undesired 
effects caused by the Hsp90 inhibitors such as induction of Hsp27 expression would need to be 
explored and addressed (Zoubeidi et al., 2007). Therefore, a global approach to elucidate the 
changes in the molecules in the cancer cells exposed to Hsp90 inhibitor is essential to evaluate the 
potential of using Hsp90 inhibitors as anti-cancer drug target.  
Although molecular changes induced by Hsp90 inhibitor was elucidated for ovarian, breast 
and colon cancers, the biochemical and cellular consequences of Hsp90 inhibitor treatment were 
known to vary with different tumours due to their heterogeneous molecular makeup (Clarke et al., 
2000; Maloney et al., 2007; Zajac et al., 2010). Therefore, a global approach to examine the 
molecular changes in HCC, in response to the Hsp90 inhibitor 17-AAG, is necessary to provide a 
comprehensive understanding on the molecular basis of Hsp90 inhibition in HCC cells.  
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As Hsp90 functions as a chaperone in eukaryotic cells, the inhibition of its activities was 
anticipated to lead to changes in expression levels of numerous proteins. In addition, bearing in 
mind that a great proportion of the Hsp90 client proteins are kinases and transcription factors 
involved in major signaling pathways and regulation of genes expression, considerable changes at 
the transcript level is also foreseeable. Hence, this study aims to employ gene expression microarray 
and antibody array to address the objective of this study. 
 
5.2 17-AAG Induced Changes in Gene Expression in Huh-7 cells 
In this study, genome-wide gene expression changes in response to 17-AAG were examined 
via microarray. The Huh-7 cells were treated with the inhibitor at 0.25 μM for 48 hrs. The use of 2.5 
times of the IC50 concentration was intended to induce greater magnitude of variation in the 
transcript expression to facilitate the identification of differentially expressed genes. The results 
obtained from the microarray were quatlile normalized across all samples. The treated samples were 
compared against the control group with DMSO treatment to identify genes that were significantly 
deregulated.  
Out of 47144 probes, 3546 (7.52%) probes had significant differences of more than 1.5-fold 
in their expression level (Figure 5.1), of which 1214 had a greater variation of 2-fold. Among these 
1214 probes, 624 were upregulated and 590 were downregulated at the mRNA expression level. To 
validate the genes identified to be deregulated by 17-AAG, 10 genes from the list were randomly 
selected and validated using qPCR (Appendix A). 9 out of the 10 genes were demonstrated to have 
consistent changes in expression level when validated with qPCR, indicating that the gene expression 
data is reliable. 
 
 






























Figure 5.1: Hierarchical Clustering of mRNA Expression Changes in Huh-7 cells Treated 
with 0.25 μM of 17-AAG. 3 independent samples of Huh-7 cells, named A, B and C, were 
sent for gene expression microarray following treatment with 17-AAG. Gene expression 
data were quatlile normalized across all samples and compared against the control group 
with DMSO treatment to identify genes that were significantly deregulated. Green and 
red signals represent genes whose expressions are decreased or increased respectively. 
Black signal, on the other hand, indicate no significant differences were observed. 
 








5.3 17-AAG Elevated Transcript Levels of Hsp70 and Other Chaperones  
Induction of Hsp70 is currently used as the pharmacodynamic marker to measure the 
endpoint response of Hsp90 inhibitors in clinical trials (Kim et al., 2009). Hsp70 was consistently 
observed to be upregulated in cancer cells in culture and also in human tumour xenografts following 
treatment with Hsp90 inhibitors (Zhang et al., 2006). This increase in Hsp70 expression was found to 
be activated by heat shock factor 1 (Hsf1) (Maloney et al., 2003). Hsf1 is constitutively expressed in 
the cell as an inactive monomer bound to Hsp90. When Hsp90 is inhibited, it would be released and 
undergo trimerization to become an active transcription factor, leading to an increased in Hsp70 
expression. Henceforth, to validate whether the 17-AAG inhibitor used in this study targets Hsp90 in 
the Huh-7 cells, the expression level of Hsp70 was examined. 
Besides Hsp70, other chaperones such as Hsp27 was also shown to be upregulated in various 
cell lines and tumour xenograft in response to Hsp90 inhibitors (Clarke et al., 2000; McCollum et al., 
2006; Zaarur et al., 2006). Importantly, enhanced Hsp27 expression was shown to sensitize the cells 
towards 17-AAG in HCC (Cui et al., 2013). With other members of the chaperone family potentially 
play a role in affecting the effectiveness of Hsp90 inhibitors, it is thus necessary to analyze their 
expression levels following the treatment with 17-AAG in Huh-7 cells. 
Members of the Hsp70 family which included HspA1A, HspA8 and HspA1B were found to 
be upregulated by 18.04, 7.90 and 11.62 folds respectively (Table 5.1, Figure 5.2). The results were 
consistent with other microarray studies conducted on other tumour cell lines (Clarke et al., 2000; 
Maloney et al., 2007; Zajac et al., 2010). The increase in Hsp70 expression level supported the notion 
that the 17-AAG used in the study inhibited the Hsp90’s activity in the Huh-7 cell line. As for Hsp27 
(Hsp1B), it was also found to be upregulated at a lower extent of 1.65 folds. Other chaperones such 
as Hsp60 and Hsp40 were also observed to have elevated expression levels. The extensive 
Chapter 5 Molecular Basis of Hsp90 Inhibition 
96 
 
upregulation of various chaperone families suggested that the 17-AAG treatment had increased the 










Table 5.1: mRNA Expression Level of Various Chaperones Family  in Response to 17-AAG 
Treatment 




Hsp110 HSPH1 Cytosol 4.62 0.0000 
Hsp90 HSP90AA1 Cytosol 2.31 0.0002 
Hsp90AB1 Cytosol 1.50 0.0052 
Hsp70 HspA1A Nucleus/cytosol 18.04 0.0000 
HspA1B Nucleus/ cytosol 11.62 0.0000 
HspA5 Endoplasmic reticulum 
No 
significant 
changes   




changes   
Hsp27 HSPB1 Cytosol 1.65 0.0000 
Hsp22 HSPB8 Cytosol 3.27 0.0001 
Hsp10 HSPE1 Cytosol 1.62 0.0010 













Figure 5.2: The Gene Response of Different Chaperone Families to 17-AAG in Huh-7 cells. Heat-
map represents the mRNA expression of various chaperones family in the 3 independent samples 
labelled A, B and C. Green and red signals represent genes whose expressions are decreased or 
increased respectively. Black signal, on the other hand, indicate no significant differences were 
observed. The intensity of the color is proportional to the degree of difference from the median. 




Fold changes 3 
 











Table 5.2:  mRNA Expression Level of Co-chaperones in Response to 17-AAG Treatment 
Co-
chaperone 




p23 PTGES3 Reduces the Hsp90’s ATPase 
activity to facilitate maturation 





al., 2006; Richter 
et al., 2004) 
Aha1 AHSA1 Enhances Hsp90’s ATPase activity 
to increase the release of client 
proteins from Hsp90 
1.73 (Lotz et al., 2003; 
Panaretou et al., 
2002) 
p50 CDC37 Inhibits Hsp90’s ATPase activity 
Binds to the middle domain of 
Hsp90 
Recruits Hsp90-dependent 




(Siligardi et al., 
2002) 
Hop STIP1 Inhibits Hsp90’s ATPase activity 
(In yeast model) 
Binds the EEVD motifs in Hsp70 
and Hsp90 
Serves as an adaptor to link 





(Richter et al., 
2003; Wegele et 
al., 2006) 
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5.4 mRNA Expression Level of Co-Chaperones in Response to 17-AAG Treatment  
Co-chaperones are a set of proteins that helps to regulate Hsp90’s chaperone activity 
(Zuehlke and Johnson, 2010). Some of them, such as p23 and Aha1, act through modulating the 
ATPase activity of Hsp90 (Table 5.2). Their involvement is hypothesized to aid the conformational 
transformation undergone by Hsp90 during the ATPase cycle and accelerate the maturation of client 
proteins. As regulators of Hsp90’s functionality, it is thus likely that co-chaperones’ expression levels 
would influence the inhibitory effects of 17-AAG. Recent studies had shown that binding of co-
chaperones such as p23 and Aha1 altered Hsp90’s affinity to its inhibitor and sensitized cells to the 
inhibitor (Forafonov et al., 2008; Holmes et al., 2008). Furthermore, Aha1 expression level was found 
to be inducible by 17-AAG (Holmes et al., 2008). Given these evidence, it is of interest to investigate 
the expression levels of these co-chaperones in response to 17-AAG treatment. 
Examination of the gene expression microarray data showed that none of the co-chaperones 
were differentially expressed after 17-AAG treatment with the exception of Aha1 (Figure 5.3). The 
result revealed that Aha1 expression was increased by 1.73 folds. The enhancement of Aha 1 
expression in the presence of 17-AAG is consistent with observations made in other studies (Holmes 





























5.5 In Silico Functional and Pathways Analyses of 17-AAG Induced Gene Expression Profile 
To investigate the effect of the changes in the genome-wide gene expression brought about 
by 17-AAG, in silico functional and pathway analyses were carried out using bioinformatics tool 
known as Ingenuity Pathway Analysis (IPA). Using the known functions and pathways from the 
Ingenuity Pathways Knowledge base, the analysis took into account the number of genes affected by 
17-AAG and the total genes present in each of the function and pathway. It then uses a right-tailed 
Fisher’s exact test to calculate the p-value of each function and pathway. This determines whether 













Figure 5.3: The Gene Response of Co-chaperones to 17-AAG in Huh-7 cells. Heat-map 
represents the mRNA expression of co-chaperones family in the 3 independent samples 
labelled A, B and C. Green and red signals represent genes whose expressions are 
decreased or increased respectively. Black signal, on the other hand, indicate no 
significant differences were observed. The intensity of the colour is proportional to the 
degree of difference from the median. Only Aha1 (AHSA1) gene was significantly 
upregulated after the 17-AGG treatment. None of the rest of the co-chaperones had 
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the gene set was enriched with genes associated with a particular function/pathway or the 
dysregulation was due to random observation. To increase the accuracy of the analysis, a stringent 
requirement of 2-fold deviation was used to define a gene with differential expression. Therefore, 
the gene expression profile induced by 17-AAG includes 1214 genes where 624 of them were 
upregulated and 590 were downregulated in mRNA expression level. 
5.5.1 17-AAG was Predicted to Affect Various Cellular Functions in HCC 
IPA analysis revealed that the gene expression profile induced by 17-AAG was significantly 
enriched with genes involved in 16 cellular processes (Appendix B). Among these biological 
processes were cellular growth and proliferation, cell death and cell cycle where 17-AAG was earlier 
characterized to have an effect against Huh-7 cells (Figure 5.4). Cellular growth and proliferation 
shared the highest association based on the p-value with a total of 274 molecules involved. 
To investigate whether the dysregulation of genes would enhance or undermine these 
biological processes, the downstream effects analysis was carried out. The analysis predicts whether 
the affected processes were activated or deactivated based on the observed gene expression 
changes in experimental dataset. The regulation of Z-score algorithm was used for predictions with 
any z-score ≥ 2 or ≤ -2 is predicted to increase or decrease the cellular processes respectively. The 
gene expression profile induced by 17-AAG was predicted to arrest cell cycle at interphase, entry and 
S-phases. Interestingly, cell migration was predicted to enhance when cells were treated with 17-
AAG (Table 5.3). This differed from the earlier result where 17-AAG was shown to reduce cell 
motility experimentally (Figure 4.14) and thus highlights the limitation of the programme. Similarly, 
although 17-AAG induced expression changes to the genes involved on cellular growth and cell 
death processes, the programme was unable to predict the expected outcome based on the changes 
in observed gene expression changes in experimental dataset.  
 

























Figure 5.4: In silico Functional Analysis of the Gene Expression Profile. Ingenuity 
Pathway Analysis (IPA) was used to analyze the gene expression profile induced by 17-
AAG in Huh-7 cells. The horizontal axis represents the significance scores for each 
function as -log (p-value). Genes involved in cellular processes such as cellular growth 
and proliferation, cell death and cell cycle were enriched in the dataset.  
 
 





5.5.2 17-AAG Predicted to Modulate ERK/MAPK, PI3K/AKT, Myc Mediated Apoptosis and 
IGF-1 signaling pathways 
Deregulation of signaling pathways is often associated with cancer pathogenesis. Defects in 
cell signaling pathways allow cancer cells to acquire the ability to 1) be self-sufficient in growth 
signal, 2) evade apoptosis and 3) become immortalized. One of the strategies in cancer therapy is to 
interfere these oncogenic-signaling pathways. Therefore, this study would like to determine the 
pathways modulated by 17-AAG in Huh-7 cells. This would help to identify pathways that were 
interfered by 17-AAG and enable it to induce inhibitory activity against Huh-7 cells. Identified 
oncogenic pathways interfered by inhibitor also allows stratification of cancer subtype that can 
potentially be targeted by 17-AAG more effectively.  
The gene expression data was mapped onto IPA library of canonical pathways to identify pathways 
modulated by 17-AAG. The IPA analysis revealed 57 canonical pathways that were significantly 
enriched in the gene expression profile (Appendix C). They included ERK/MAPK, PI3K/AKT, Myc 
Table 5.3: Cellular Processes Enriched by Genes that were Differentially Expressed Following 










Cell Cycle interphase 0.03980 Decreased -2.25 57 
Cell Cycle entry into S phase 0.07650 Decreased -2.22 12 
Cell Cycle S phase 0.00770 Decreased -2.03 28 
Cell Death 
and Survival 
apoptosis of tumour 
cell lines 0.00997 
Unable to 




proliferation of cells 
0.00000 
Unable to 




endothelial cells 0.00000 Increased 2.53 33 
Cellular 
Movement 
cell movement of 
endothelial cells 0.00000 Increased 1.99 35 
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Mediated Apoptosis and IGF-1 signaling pathways (Table 5.4). These pathways were functionally 
annotated in processes such as apoptosis, cell cycle and cell growth. It is likely that 17-AAG exerted 
its biological activity on Huh-7 cells through these pathways. Interestingly, 17-AAG also affected 
many of the stress response pathways such as NRF2-mediated oxidative stress response.  
Remarkably, the wide range of pathways that were affected by 17-AAG indicated the far-reaching 
implication in targeting Hsp90 inhibitor. 
 
Table 5.4: Ingenuity Canonical Pathways Enriched by Genes that were Differentially Expressed 
Following Treatment with 17-AAG 
Category Ingenuity Canonical Pathways p-value Ratio 
Apoptosis TNFR2 Signaling 0.0004 0.2500 
Apoptosis TNFR1 Signaling 0.0042 0.1760 
Apoptosis Aryl Hydrocarbon Receptor Signaling 0.0043 0.1280 
Apoptosis LPS-stimulated MAPK Signaling 0.0269 0.1270 
Apoptosis PTEN Signaling 0.0295 0.1080 
Apoptosis Toll-like Receptor Signaling 0.0331 0.1400 
 
Cancer Role of BRCA1 in DNA Damage Response 0.00724 0.1590 
Cancer ERK/MAPK Signaling 0.02951 0.1010 
Cancer PTEN Signaling 0.02951 0.1080 
Cancer PI3K/AKT Signaling 0.03802 0.1040 
 
Cell cycle Role of CHK Proteins in Cell Cycle Checkpoint Control 0.00110 0.1930 
Cell cycle Aryl Hydrocarbon Receptor Signaling 0.00427 0.1280 
Cell cycle ATM Signaling 0.01862 0.1480 
Cell cycle Role of CHK Proteins in Cell Cycle Checkpoint Control 0.00110 0.1930 
Cell cycle Aryl Hydrocarbon Receptor Signaling 0.00427 0.1280 
 
Cell Growth ILK Signaling 0.0126 0.1140 
Cell Growth PI3K/AKT Signaling 0.0380 0.1040 
 
Stress  NRF2-mediated Oxidative Stress Response 0.0005 0.1340 
Stress  Role of CHK Proteins in Cell Cycle Checkpoint Control 0.0011 0.1930 
Stress  Antioxidant Action of Vitamin C 0.0048 0.1430 
Stress  Role of BRCA1 in DNA Damage Response 0.0072 0.1590 
Stress  ATM Signaling 0.0186 0.1480 
Stress  Mismatch Repair in Eukaryotes 0.0209 0.2000 
Stress  UVB-Induced MAPK Signaling 0.0245 0.1480 
Stress  HIF1α Signaling 0.0407 0.1180 


















Table 5.5: Upstream Transcription Regulators Predicted to be Activated or 







Bias-corrected      
z-score 
TNF - 0.0000 Inhibited -2.93 
TRIB3 -3.39 0.0000 Activated 3.21 
PDGF BB - 0.0000 Inhibited -3.04 
PGR - 0.0000 Inhibited -2.00 
NFkB (complex) - 0.0000 Inhibited -3.14 
ATF4 - 0.0000 Inhibited -2.54 
FOXL2 - 0.0000 Inhibited -3.08 
IL1A - 0.0000 Inhibited -3.05 
Mek - 0.0000 Inhibited -3.13 
IL1B - 0.0000 Inhibited -2.05 
MXI1 - 0.0001 Activated 2.36 
COL18A1 2.06 0.0001 Activated 2.14 
GNE - 0.0001 Activated 1.96 
TP63 - 0.0002 Inhibited -2.28 
TRAF3 - 0.0002 Activated 2.20 
TAZ - 0.0002 Activated 2.04 
CXCL12 2.48 0.0003 Inhibited -2.06 
HGF - 0.0011 Inhibited -2.24 
MBD2 - 0.0011 Inhibited -2.19 
NEDD9 - 0.0013 Inhibited -2.06 
YAP1 - 0.0014 Activated 2.04 
EGF - 0.0019 Inhibited -2.33 
PPRC1 - 0.0022 Inhibited -2.88 
IL6 - 0.0025 Inhibited -2.74 
KDM5A - 0.0028 Activated 1.99 
TGM2 - 0.0052 Activated 2.75 
EGFR 2.44 0.0052 Inhibited -2.14 
CD40LG - 0.0061 Inhibited -2.44 
TLR7 - 0.0069 Inhibited -2.19 
PRKCE - 0.0099 Inhibited -2.15 
F7 - 0.0245 Inhibited -2.13 
CREB1 - 0.0276 Inhibited -1.96 





5.5.3 Transcription Regulators predictably modulated by 17-AAG  
The gene expression changes induced by 17-AAG were likely an indirect consequence of the 
degradation of Hsp90 client proteins. 17-AAG inhibited Hsp90’s functionality, leading to the 
depletion of transcription factors and kinases that are chaperoned by Hsp90 and consequently 
caused the deregulation of the expression of the downstream targets. Hence, in order to identify key 
proteins that were directly affected by 17-AAG, IPA Upstream Regulator Analysis was performed. 
The gene expression profile obtained earlier was used to predict the upstream transcriptional 
regulators that were responsible for the differentially expressed genes. 
The analysis predicted that there were 33 upstream transcriptional regulators that were 
either undermined or enhanced in functionality (Table 5.5). Among these regulators were known 
client proteins of Hsp90 such as EGFR and mitogen-activated protein kinase kinase (Mek). Consistent 
with other studies, inactivation of cytokines such as TNF and protein complex NF-KB was also 
identified (Chen et al., 2002; Wang et al., 2006). Interestingly, there were a number of regulators 
that are not known to have direct relationship with Hsp90, suggesting the possibility of potential 
new client proteins or interaction network. Some discrepancies were found in the analysis result. For 
instance TRIB3 was expected to be downregulated after the inactivation of ATF4 (Jousse et al., 2007; 
Ohoke et al., 2005). However, the analysis predicted that activity of TRIB3 was activated. This 
suggested a potential inherent auto-feedback mechanism in the cells that was triggered in response 










5.6 Protein Expression Profiling of Huh-7 Cells treated with 17-AAG  
2 samples of Huh-7 cell lysates were analyzed using antibody array following the treatment 
with 0.25 μM of 17-AAG for 48 hrs to detect for changes in the expression levels of 362 proteins. 
Figure 5.5 illustrated the protein expression profile of the 2 samples in comparison to cells treated 
with DMSO. Using a 1.5-fold cutoff and a Z-ratio ≥ 1 or ≤ -1, 47 proteins were identified to have 
altered expression levels (Table 5.6). The number of differentially expressed proteins account for 












Figure 5.5: Heat-map Representation of The Protein Expression Changes in Huh-7 cells 
Treated with 0.25 μM of 17-AAG. 2 independent samples labelled A and B were sent for 
antibody array. Green and red signals represent genes whose expressions are decreased 
or increased respectively. Black signal, on the other hand, indicate no significant 
differences were observed. The intensity of the color is proportional to the degree of 
difference from the median. A total of 47 out of the 362 (12.98%) detectable proteins 
was found to be signficantly deregulated (/Fold change />1.5 and /z-ratio/ >1) in both of 





























Table 5.6A: Proteins that were Significantly Upregulated Following Treatment with 17-AAG 
Protein Name Gene ID Refseq 







ROR2 neurotrophic receptor-tyrosine kinase ROR2 NP_004551 79.74 6.58 49.06 5.90 Kinase 
Protein-serine phosphatase 2C - catalytic 
subunit - alpha 
PPM1A NP_066283 33.67 5.01 20.06 4.42 Phosphatase 
Superoxide dismutase [Mn] Sod2 NP_000627 10.19 3.90 3.31 1.90 Other 
Cyclin-dependent protein-serine kinase 2 Cdk2 NP_001789 6.22 3.06 5.43 2.70 Kinase 
DNA fragmentation factor alpha (ICAD) 35-
kDa subunit 
DFFA NP_004392 5.19 2.06 4.73 2.20 Other 
Cell division cycle 34 (ubiquitin-conjugating 
ligase) 
CDC34 NP_004350 4.83 2.51 3.38 1.89 Other 
Heat shock 70 kDa protein 1 HSPA1A NP_005336 3.96 2.14 4.18 2.22 Chaperone 
Glycogen synthase-serine kinase 3 alpha GSK3A NP_063937 3.77 2.00 5.70 2.70 Kinase 
Cell division control protein 42 homolog Cdc42 NP_001782 3.45 1.86 2.67 1.48 Other 
cAMP-dependent protein-serine kinase 
catalytic subunit alpha/beta 
PRKACA NP_002721 3.38 1.90 2.63 1.49 Kinase 
Cyclin-dependent protein-serine kinase 2 Cdk2 NP_001789 3.20 1.77 3.03 1.70 Kinase 
Cyclin-dependent protein-serine kinase 1 Cdk1 NP_001777 2.87 1.64 1.95 1.02 Kinase 
p21-activated kinase 1/2/3 (serine/threonine-
protein kinase PAK 1/2/3) 
Pak1 NP_002567 2.84 1.41 2.80 1.52 Kinase 
NIMA (never-in-mitosis)-related protein-
serine kinase 7 
NEK7 NP_598001 2.79 1.26 2.11 1.01 Kinase 
Janus protein-tyrosine kinase 1 JAK1 NP_002218 2.51 1.54 1.93 1.06 Kinase 
ER protein 72 kDa (protein disulfide 
isomerase-associated 4) 
Pdia4 NP_004902 2.44 1.10 2.95 1.58 Other 
Hsp70 binding protein 1 HSPBP1 NP_036399 2.43 1.29 2.54 1.42 Chaperone 
Four and a half LIM domains protein 2 FHL2 NP_001034581 2.42 1.31 2.15 1.16 
Transcription 
regulator 
Jun proto-oncogene-encoded AP1 
transcription factor 
Jun NP_002219 2.42 1.30 2.59 1.46 
Transcription 
regulator 
Leukocyte common antigen CD45 receptor-
tyrosine phosphatase (LCA, T200) 
Ptprc NP_002829 2.23 1.13 2.20 1.18 Phosphatase 
Cell division cycle 25B phosphatase Cdc25b NP_004349 2.01 1.10 2.37 1.36 Phosphatase 
Heat shock 47 kDa protein (collagen-binding 
protein 1, colligin 1) 













Table 5.6B: Proteins that were Significantly Downregulated Following Treatment with 17-AAG 
Protein Name Gene ID Refseq 







Bone marrow X protein-tyrosine kinase BMX NP_001712 -1.50 -1.27 -1.56 -1.33 Kinase 
Mammalian STE20-like protein-serine kinase 1 
(KRS2) 
STK4 NP_006273 -1.50 -1.51 -1.50 -1.24 Kinase 
Interleukin 1 receptor-associated kinase 4 IRAK4 NP_057207 -1.50 -1.51 -1.57 -1.48 Kinase 
B lymphoid tyrosine kinase Blk NP_001706 -1.50 -1.47 -1.67 -1.87 Kinase 
Heat shock transcription factor 4 HSF4 NP_001529 -1.52 -1.27 -1.61 -1.50 
Transcription 
regulator 
Cyclin-dependent protein-serine kinase 5 cdk5 NP_004926 -1.52 -1.16 -1.53 -1.17 Kinase 
RafB proto-oncogene-encoded protein-serine 
kinase 
BRAF NP_004324 -1.54 -1.56 -1.60 -1.55 Other 
MAPK/ERK kinase kinase 4 MAP3K4 NP_005913 -1.60 -1.84 -1.57 -1.45 Kinase 
MAP kinase phosphatase  1 (CL100, VH1) DUSP1 NP_004408 -1.61 -1.55 -1.58 -1.37 Phosphatase 
B-cell lymphoma protein 2 alpha Bcl2 NP_000624 -1.61 -1.50 -1.57 -1.31 Other 
Heat shock 90 kDa protein beta HSP90AB1 NP_031381 -1.61 -1.46 -1.72 -1.96 Chaperone 
Ribosomal protein-serine S6 kinase beta 2 RPS6KB2 NP_003943 -1.61 -1.87 -1.56 -1.41 Kinase 
RafB proto-oncogene-encoded protein-serine 
kinase 
BRAF NP_004324 -1.61 -1.58 -1.58 -1.36 Other 
Heat shock 90 kDa protein alpha/beta HSP90AA1 NP_005339 -1.64 -1.69 -1.62 -1.54 Chaperone 
DNA mismatch repair protein mutS homolog2, 
colon cancer, nonpolyposis type 1 
Msh2 NP_000242 -1.64 -1.69 -1.74 -2.15 Other 
MAP kinase-interacting protein-serine kinase 
2 (calmodulin-activated) 
MKNK2 NP_060042 -1.64 -1.81 -1.52 -1.18 Kinase 
RhoA protein-serine kinase beta ROCK1 NP_005397 -1.65 -1.66 -1.79 -2.43 Kinase 
5'-AMP-activated protein kinase (AMPK), 
beta-1 regulatory subunit 
PRKAB1 NP_006244 -1.66 -2.23 -1.70 -2.09 Kinase 
Checkpoint protein-serine kinase 1 CHEK1 NP_001265 -1.66 -1.75 -1.58 -1.36 Kinase 
Transcription factor RelB RELB NP_006500.2 -1.67 -1.75 -1.65 -1.62 
Transcription 
regulator 
Mammalian STE20-like protein-serine kinase 3 stk24 NP_003567 -1.67 -1.94 -1.68 -1.86 Kinase 
Cyclin-dependent protein-serine kinase 7 CDK7 NP_001790 -1.68 -1.78 -1.65 -1.61 Kinase 
Inhibitor of NF-kappa-B protein-serine kinase 
alpha (CHUK) 
CHUK NP_001269 -1.68 -1.84 -1.53 -1.17 Kinase 
Mammalian STE20-like protein-serine kinase 1 
(KRS2) 
STK4 NP_006273 -1.69 -2.06 -1.75 -2.25 Kinase 
Orosomucoid 1 receptor-tyrosine kinase ROS1 NP_002935 -1.79 -2.93 -1.83 -2.95 Kinase 
Caspase 1 (Interleukin-1 beta convertase) CASP1 NP_001214 -1.79 -2.92 -1.88 -3.50 Other 
Glycogen synthase-serine kinase 3 beta GSK3B NP_002084 -1.83 -3.30 -1.68 -1.92 Kinase 
Ras-related protein Rab-5A RAB5A NP_004153 -1.91 -4.42 -1.94 -4.71 Other 
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5.7 17-AAG Treatment Upregulated Hsp70 at Both the Transcript and Protein Levels 
 Members of the Hsp70 chaperone family (HspA1A, HspA8 and HspA1B) have been shown to 
be upregulated at the transcript level in this study (Table 5.1). Using the antibody array, expression 
of the Hsp70 and other chaperone families at the protein level was also examined. The protein array 
revealed consistent findings of Hsp70 upregulation (Figure 5.6). Hsp70 (HSPA1A/HSPA1B) was found 
to be upregulated by an average of 4.07 folds. Besides Hsp70, a member of Hsp40, SERPINH1 was 
also found to have increased expression of 1.88 fold. Interestingly, Hsp90 expression was decreased 









































Figure 5.6: The Protein Expression of Chaperones in Response to 17-AAG Treatment in 
Huh-7 cells. Heat-map represents the protein expression of various chaperone families in 
the 2 independent samples labelled A & B. Green and red signals represent genes whose 
expressions are decreased or increased respectively. Black signal, on the other hand, 
indicate no significant differences were observed. The intensity of the color is 
proportional to the degree of difference from the median.  
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5.8 In Silico Functional and Pathways Analyses of 17-AAG Induced Protein Expression Profile  
 IPA analysis of the protein expression profile induced by 17-AAG revealed that the proteins 
affected by the inhibitor were associated with 27 cellular processes (Appendix D). Similar to the 
analysis based on the gene expression profile, functions such as apoptosis, cell growth, cell cycle and 
cell movement were predictably altered as a result of the pool of deregulated proteins induced by 
17-AAG. In particular, the protein expression profile suggested that apoptosis of cells was likely to 
increase.  The proteins that could account for the increase in cell death included the anti-apoptotic 
regulator Bcl-2 and the protein kinase, BRAF.  
The IPA analysis of the protein expression profile also revealed several pathways that were 
likely to be modulated (Table 5.7). Similar to the analysis of the gene expression profile, they 
included pathways that were functionally annotated to act in processes such as apoptosis, cell cycle 
and cell growth (Table 5.8). Taken together with the results of the gene expression profile, pathways 
such as PI3K/AKT, PTEN, Aryl Hydrocarbon Receptor, ATM and TNFR1 signaling were likely to play a 
major role in 17-AAG biological activities as they were repeatedly identified in the analysis of both 
dataset. Interestingly, given that Hsp90 chaperoned ERK5 and MEK, the ERK/MAPK pathway was 
surprisingly not found to be significantly enriched. This is in contrary with the analysis results using 
the gene expression dataset. Nevertheless, other MAPK signaling pathways which included LPS-
stimulated MAPK and p38 MAPK signaling were identified instead. To further validate the analysis 
result, another prediction programme known as Database for Annotation, Visualization and 
Integrated Discovery (DAVID) was used to identify pathways that were enriched. This programme 
uses a different algorithm, which is more conservative compared to the Fisher’s exact test used in 
the IPA analysis, to calculate the p-value of each of the pathways and include multiple test 
correction (Bonferroni correction) which reduces false discovery that are often resulted from 
multiple testing. The programme revealed that the protein expression profile was statistically 
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significant and overrepresented with deregulated proteins associated with MAPK signaling and 









Table 5.7: Molecular and Cellular Processes Enriched by Genes that were Differentially Expressed 






















tumour cell lines 
0.00000 Unable to predict 1.256 8 
Cellular 
Movement 
cell movement 0.00000 Unable to predict 0.670 17 
Cellular 
Movement 











tumour cell lines 
0.00000 Unable to predict -0.293 19 
 





Table 5.8: Ingenuity Canonical Pathways Enriched by Genes that were Differentially Expressed 
Following Treatment with 17-AAG 
Category Ingenuity Canonical Pathways p-value Ratio 
Apoptosis PTEN Signaling 0.00000 0.0462 
Apoptosis Apoptosis Signaling 0.00001 0.0543 
Apoptosis TNFR1 Signaling 0.00001 0.0784 
Apoptosis Aryl Hydrocarbon Receptor Signaling 0.00005 0.0355 
Apoptosis LPS-stimulated MAPK Signaling 0.00007 0.0506 
 
Cancer Molecular Mechanisms of Cancer 9.6000 0.00000 
Cancer PI3K/AKT Signaling 8.5400 0.00000 
Cancer PTEN Signaling 5.8400 0.00000 
Cancer p53 Signaling 5.0400 0.00001 
 
Cell cycle Cell Cycle: G2/M DNA Damage Checkpoint Regulation 0.00001 0.0833 
Cell cycle GADD45 Signaling 0.00003 0.1430 
Cell cycle ATM Signaling 0.00003 0.0656 
Cell cycle Mitotic Roles of Polo-Like Kinase 0.00004 0.0625 
Cell cycle Aryl Hydrocarbon Receptor Signaling 0.00005 0.0355 
 
Cell Growth PI3K/AKT Signaling 0.00000 0.0593 
Cell Growth HGF Signaling 0.00001 0.0490 
 
Stress  p38 MAPK Signaling 0.00003 0.0431 
Stress  ATM Signaling 0.00003 0.0656 
Stress  Hypoxia Signaling in the Cardiovascular System 0.00004 0.0625 
Stress  Role of CHK Proteins in Cell Cycle Checkpoint Control 0.00063 0.0526 
Stress  NRF2-mediated Oxidative Stress Response 0.00209 0.0214 
Table 5.9: KEGG Pathways Enriched by Genes that were Differentially Expressed Following 
Treatment with 17-AAG 
Pathway 
Number of 
genes % of gene affected 
Fold 
enrichment (%) Bonferroni 
MAPK signaling pathway 14 2.4911 7.2062 0.0000 
Pathways in cancer 12 2.1352 5.0280 0.0007 
Cell cycle 6 1.0676 6.5968 0.1150 
Apoptosis 5 0.8897 7.8984 0.2004 
KEGG: Kyoto Encyclopedia of Genes and Genomes 
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5.9 17-AAG Treatment Led to the Upregulation of SOD Protein Expression 
 IPA analysis revealed that in both the gene expression and protein array data, there was an 
enrichment of molecules involved in NRF2-mediated oxidative stress response. One of the key 
molecules involved in this pathway is superoxide dismutase (SOD). Interestingly, protein array 
showed that SOD Mn (SOD2) was upregulated but at the transcript level, it was downregulated 
(Table 5.10). Other members of the SOD family were not differentially expressed at the transcription 
level.  
To validate the expression level of SOD, western blot analysis using SOD antibodies was 
carried out. SOD protein level was shown to increase in the presence of 17-AAG (Figure 5.7). The 
result indicated that while 17-AAG decreased the transcript level of SOD, the SOD proteins have 
accumulated in the cells and therefore lead to an increase in overall expression at protein level. The 
decrease in expression of the SOD2 transcript could be as a result of negative feedback process 











Table 5.10: Expression of the Superoxide Dismutase Family after the 
Treatment with 17-AAG 
Gene ID 
Fold Change 
Protein level Transcript level 
SOD1 No significant changes 1.24 
SOD2 6.75 -3.35 
SOD3 Not detected 1.01 










5.10 Biological Significance of SOD Upregulation 
Excessive levels of reactive oxygen species (ROS) are harmful to the cells, as it damages 
cellular proteins, lipids and DNA. One of the cellular anti-oxidative mechanisms is to break down the 
ROS through SOD. SOD functions as an enzyme that breaks down the ROS (e.g. superoxide), into 
oxygen and hydrogen peroxide through dismutation and thus protects the cell from oxidative stress. 
Similarly, Hsp90 also offers protection against oxidative stress by playing a role in buffering the 
detrimental effects of ROS (Beck et al., 2011). Excessive ROS levels would induce protein aggregation 
and misfolding. An increase level of Hsp90 during oxidative stress enables protein homeostasis 
within the cell to be maintained by reducing protein aggregation or direct aberrant proteins for 
degradation. In addition, Hsp90 negatively regulates apoptosis by binding and inhibiting members of 
the apoptotic cascade and thus, is able to mitigate the effect of oxidative stress in inducing apoptosis 
on the cells.  
Given Hsp90’s implication in protection against oxidative stress, it was intriguing to find that 
inhibition of Hsp90’s activity via 17-AAG would also offer greater protection against oxidative stress 
through increased level of SOD (Beck et al., 2009). To investigate the biological significance of the 
 DMSO 
Figure 5.7: The Expression of SOD in Response to 17-AAG Treatment in Huh-7 cells. 
SOD protein level was found to increase after the cells were treated with 0.1 μM and 1 




 1 μM  0.1 μM 
Anti-SOD 
Anti-GAPDH 
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upregulation of SOD, tert-Butyl hydroperoxide (TBHP) was used to induce oxidative stress in the 
cells. The increase in oxidative stress would consequently lead to cellular apoptosis. Huh-7 cells were 
treated with 0.1 μM or 1 μM of 17-AAG for 48 hrs and subsequently, incubated with TBHP for 4 hrs 
to induce apoptosis via oxidative stress. Approximately 100 or more cells from each treatment group 
were examined for apoptotic features. Apoptotic cells were determined and measured by analysis of 
nuclear morphology (Hoechst staining) and mitochondrial membrane potential (TMRE staining) 
(Figure 5.8).  
For Huh-7 cells exposed to 17-AAG, there was substantially lesser amount of apoptotic cells 
after incubation with TBHP (Figure 5.9). The proportion of cells that underwent apoptosis was 49.1% 
and 23.2 % in the cells treated with 0.1 μM and 1 μM of 17-AAG respectively, as compared to 100% 
in cells exposed to DMSO. To rule out the possibility of an “off-target” effect of 17-AAG, cells were 
also subjected to radicicol treatment instead of 17-AAG. Similar protective effects were also 
observed where the amount of cells that underwent apoptosis after exposure to TBHP was reduced 
to 76.6% and 44.2% in the cell treated with 0.1 μM and 1 μM of radicicol respectively. The increase 
in 17-AAG and radicicol concentration significantly helped to mitigate the apoptotic effect induced 
by TBHP.  
Next, the study examined if the observed phenomenon extends to other HCC cell lines. 
HepG2 cells were treated with both the Hsp90 inhibitors and subsequently, incubated with TBHP to 
induce oxidative stress. Results revealed that comparable trend was observed in HepG2 cells where 
treatment with 0.1 μM and 1 μM of 17-AAG reduced the number of apoptotic cells to 76.4% and 
23.2% respectively, a reduction from 92.1% in the DMSO treated cells when exposed to THBP (Figure 
5.10). Radicicol treatment also protected the cells against TBHP-induced apoptosis as lower amount 
of 73.7% and 44.2% of apoptotic cells were observed in presence of 0.1 μM and 1 μM of radicicol 
respectively.  
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To further validate the results obtained for both Huh-7 and HepG2 cells, flow cytometry 
analysis using annexin V-PE and 7AAD fluorescein was employed to profile a greater population of 
cells. The analysis revealed a comparable proportion of cells that underwent apoptosis as observed 
in the earlier results (Figure 5.11 & Figure 5.12).  TBHP induced 51.6% of Huh-7 cell population 
treated with 0.1 μM of 17-AAG to undergo apoptosis as compared to 90.8% in the DMSO treated 
cells. The number of cells underwent TBHP-induced apoptosis were lower at 39.8% when the cells 
were exposed to a higher concentration of 1 μM of 17-AAG. The proportion of apoptotic cells in 0.1 
μM and 1 μM radicicol treatment group were 91.6% and 52.7% respectively after the exposure to 
TBHP. Similarly, in the HepG2 cells, treatment with 0.1 μM and 1 μM of 17-AAG has lower amount of 
apoptotic cells (74.8% and 66.7% respectively) as compared to 82.6% that was observed in DMSO 
treated cells when exposed to THBP. Taken together, the results support that Hsp90 inhibition 

























Figure 5.8A: Morphological features of Pre-treated Huh-7 Cells After Incubation with 
100 μM of TBHP For 4 hours. Huh-7 cells were pre-treated with the Hsp90 inhibitors, 17-
AAG and radicicol (RAD) respectivity for 48 hrs prior to the addition of the TBHP. DMSO 
was used as the vehicle control. TMRE staining was carried out to examine the 
mitochondrial membrane potential whereas Hoechst 33258 was used to visualize nuclear 
morphology and DNA condensation. Viable cells would be stained with TMRE (red) and 
less intense Hoechst 33258 staining (blue). Absence of TMRE staining and intensified 
Hoechst 33258 staining were indicative of dying cells which were indicated with the 
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Figure 5.8B: Morphological features of Pre-treated HepG2 Cells After Incubating with 
200 μM of TBHP For 4 hours. HepG2 cells were pre-treated with Hsp90 inhibitors, 17-
AAG and radicicol (RAD) respectivity for 48 hrs prior to the addition of the TBHP. DMSO 
was used as the vehicle control. TMRE was used to examine the mitochondrial 
membrane potential whereas Hoechst 33258 was used to visualize nuclear morphology 
and DNA condensation. Viable cells would be stained with TMRE (red) and less intense 
Hoechst 33258 staining (blue). Absence of TMRE staining and intensified Hoechst 33258 
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Figure 5.9: Apoptosis Profile of Pre-treated Huh-7 Cells After Incubation with 200 μM of 
TBHP For 4 hours. Huh-7 cells were pre-treated at various conditions as indicated by the 
horizontal axis. Approximately 100 or more cells for each treatment group were 
examined to quantify the total number of apoptotic cells present in each population. 
Values indicated are the mean ± SD of three independent experiments. There are 
significantly lower amount of apoptotic cells in the 17-AAG and radicicol (RAD) treatment 
group as compared to the DMSO pre-treated cells. Higher concentration of 17-AAG and 
radicicol also resulted in significantly lower percentage of apoptotic cells induced by 
TBHP mediated oxidative stress.  
 
 

















Figure 5.10: Apoptosis Profile of Pre-treated HepG2 Cells After Incubation with 100 μM 
of TBHP For 4 hours. HepG2 cells were pre-treated at various conditions as indicated by 
the horizontal axis. Approximately 100 or more cells for each treatment group were 
examined to quantify the total number of apoptotic cells present in each population. 
Values indicated are the mean ± SD of three independent experiments. Pre-treatment 
with 1 μM of 17-AAG or radicicol (RAD) would significantly lower the amount of 
apoptotic cells as compared to the DMSO pre-treated cells. Higher concentration of 17-
AAG and radicicol also resulted in significantly lower percentage of apoptotic cells 
induced by TBHP mediated oxidative stress.  
 






















Figure 5.11: Flow Cytometry Profiling of the Apoptotic Huh-7 Cells in Various Pre-
treatment Groups After Incubation with 600 μM of TBHP For 4 hours. A) Huh-7 cells 
were pre-treated at various drug conditions as indicated. Flow cytometry using annexin 
V-PE and 7AAD fluorescein was used to profile 10000 cells from each treatment group. 
Apoptotic cells are shown in the lower right (Early-phase) and upper right (Late-phase) 
quadrant. B) Values indicated are the mean ± SD of three independent experiments. 
There were significantly lower precentage of apoptotic cells in the 17-AAG and radicicol 
(RAD) treatment groups as compared to the DMSO pre-treated cells. Higher 
concentration of radicicol also resulted in significantly lower level of cell death induced 

































Figure 5.12: Flow Cytometry Profiling of the Apoptotic HepG2 cells in Various Pre-
treatment Groups After Incubation with 800 μM of TBHP For 4 hours. HepG2 cells were 
pre-treated at various drug conditions as indicated. Flow cytometry using annexin V-PE 
and 7AAD fluorescein was used to profile 10000 cells from each treatment group. 
Apoptotic cells are shown in the lower right (Early-phase) and upper right (Late-phase) 
quadrant. B) Values indicated are the mean ± SD of three independent experiments. Pre-
treatment with 1 μM of 17-AAG would significantly lower level of cell death as compared 









Understanding the mode of action of Hsp90 inhibitors in HCC cells is the key to examine the 
potential of Hsp90-targeted therapy in treating the most common form of liver cancer. It is 
important to elucidate the oncoproteins and pathways in the HCC cells that are affected by Hsp90 
inhibitors and at the same time, identify those proteins unaffected by the inhibitors as some of them 
may potentially continue to support HCC pathogenesis. This information is vital for the design of 
Hsp90-targeted therapy as it would help to predict whether Hsp90 inhibitor when used singly is 
sufficient to produce the desired outcome in HCC patients or has to be complemented with other 
anti-cancer drugs. Furthermore, the information could help to stratify HCC cancer subtype to 
improve the overall efficacy of Hsp90-targeted therapy. In addition, the knowledge gained could 
help to identify better biomarker that is essential to measure the pharmacological response to the 
Hsp90 inhibitor in HCC patient. Therefore, this study attempted to map out the molecular basis of 
17-AAG biological effects on HCC using a global approach consisting of gene expression and antibody 
arrays.   
Microarray results revealed that exposure to 0.25 μM (2.5 times of the IC50) of 17-AAG 
caused more than 3000 genes (7.52% of the total probes) to dysregulate at the transcript level. In 
addition, 47 out of 362 (12.98%) detectable proteins were found to have differential expression 
using the antibody array. The expression level of these proteins did not correlate well with their 
transcript levels profiled by the microarray, highlighting the dynamic and complexity of targeting 
Hsp90. Nevertheless, it also illustrated the value of having an integrated profiling approach of both 
the transcript and protein to study the molecular basis of 17-AAG in inhibiting the cellular activities 
of the cells.  
In this study, Hsp70 was found to be upregulated at both the transcript and protein levels, 
which is consistent with other reported studies (Zhang et al., 2006). Given that Hsp70 is the most 
commonly used biomarker to measure the endpoint of Hsp90 inhibition, the result thus confirmed 
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that the 17-AAG used in this study was pharmacologically active in inhibiting the Hsp90 in the Huh-7 
cell line (Dakappagari et al., 2010). Besides Hsp70, other chaperone transcripts such as Hsp27 were 
also found to be elevated. The overexpression of Hsp70 and Hsp27 is a concern as their increased 
presence could potentially reduce the effectiveness of 17-AAG. Hsp70 is known to offer protection 
to tumour cells against 17-AAG through inhibiting death receptor and mitochondria-initiated 
signaling for apoptosis (Saleh et al., 2000). It acts by binding to the Apaf1 and consequently, 
prevents the constitution of the Apaf-1/cytochrome c/caspase-9 activation complex. Similarly, Hsp27 
overexpression has also been shown to help cells to resist the inhibitory effects of 17-AAG (Cui et al., 
2013). In addition, Hsp27 was also found to bind and prevent the activation of pro-caspase 3 and 
thus limit 17-AAG in inducing apoptosis (Voss et al., 2007). Nevertheless, the magnitude of increase 
for Hsp27 is much lower (1.65 fold) as compared to other chaperones and therefore, requires 
further investigation to determine if the elevation would have a significant effect on the activity of 
17-AAG.  
The extensive upregulation of various chaperone families indicated that the exposure to 17-
AAG induced major stress response in the Huh-7 cells, mediated by Hsf1. Study had shown that Hsf1 
facilitates carcinogenesis through promoting cell proliferation and survival in the human cell lines 
and xenograft model (Dai et al., 2007). Given that Hsf1 is a master regulator in activating various 
chaperones and pro-survival proteins such as Bcl-2 (Page et al., 2006), the induction of Hsf1 would 
not only nullify the proteotoxic stress that Hsp90 inhibition induced but increase pro-survival 
proteins that could help cancer cells to cope with the oncoproteins degradation mediated by the 
Hsp90 inhibitors. The silencing of Hsf1 through RNA interference has been shown to increase cancer 
cells’ susceptibility towards 17-AAG (Chen et al., 2013). Therefore, the potential oncogenic side 
effects of Hsf1 induction and other chaperones will have to be considered in the development of 
Hsp90-targeted therapies.  
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Besides chaperones, co-chaperones also could affect the sensitivity of cancer cells to 17-AAG 
through altering the function of Hsp90 (Forafonov et al., 2008; Holmes et al., 2008). Therefore, 
mRNA expression level of co-chaperones was examined in this study. None of the co-chaperones 
that inhibited Hsp90 ATPase activity was dysregulated by 17-AAG. Instead, the mRNA level of Aha1, 
the  co-chaperone that is known to directly stimulate the ATPase activity of Hsp90, was found to 
increase in the presence of 17-AAG (Li et al., 2013). The presence of heat shock element (HSE) sites 
in its promoter region suggested that Aha1 could have been upregulated by Hsf1. Although 
depleting Aha1 increases the sensitivity of cancer cells towards Hsp90 inhibition, overexpression of 
the co-chaperone was not found to alter the affinity of the cells towards 17-AAG (Holmes et al., 
2008). Nevertheless, given that Aha1 functions to accelerate the hydrolysis of ATP in Hsp90, this 
suggested that 17-AAG had interfered Hsp90 ATPase activity and consequently, disrupted the ATP-
driven structural changes of the chaperone that is essential for its functionality. As a likely protective 
mechanism, Aha1 was upregulated where its ATPase stimulatory effect can compensate for the 
diminished activity in the compromised Hsp90. This highlighted the importance of Aha1 in 
maintaining the functional integrity of Hsp90. 
The study subsequently examined the gene and protein expression profiles induced by 17-
AAG to identify key cellular processes and pathways that were interfered by the compound. Based 
on both the gene and protein expression profiles, IPA bioinformatics programme predicted that 17-
AAG is likely to affect cellular functions such as apoptosis, cell growth, cell cycle and cell movement. 
Consistent with the results obtained from the characterization of the in vitro cellular effects of 17-
AAG on Huh-7 cells, analysis of the protein expression profile indicated that apoptotic activity of the 
cells was likely to increase and the gene expression profile suggested the occurrence of cell cycle 
arrest. The key genes deregulated by 17-AAG, which are involved in cell cycle process, include 
receptors for signaling pathways such as EGFR and HER2 (ERBB2) and transcription factor, MYC, 
which was frequently mutated to become constitutive activated in cancer cells. Furthermore, the 
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potential cancer therapeutic targets, 1) FOMX1, which regulates cyclin E expression, and 2) 
p21/WAF1 (CDKN1A), inhibitor of cyclin-dependent kinases, were also among the list of genes that 
were deregulated by 17-AAG. In addition, the modus operandi of 17-AAG in promoting cell death 
included lowering the expression of key anti-apoptotic regulator Bcl-2 and clinically targeted protein 
kinase, BRAF.  
Several pathways were predicted to be modulated by 17-AAG based on separate analysis of 
the gene and protein expression datasets. Two pathways, ERK/MAPK and PI3K/AKT/mTOR signaling 
pathways, were identified in both of the analyses, which increases the confidence that the pathways 
were modulated by 17-AAG. Importantly, both of the pathways were found to be involved in the 
HCC pathogenesis (Whittaker et al., 2010). ERK/MAPK signaling pathway, which regulates cell 
growth, was found to be activated by HCC causative factors, HBV and HCV (Aoki et al., 2000; Stockl 
et al., 2003). The upstream activators of the pathway such as IGF-2, HGF, EGF, VEGF, PDGF were also 
generally found elevated in HCC patients (Alexia et al., 2004; Tanaka and Arii, 2012). Some of these 
factors also activate the PI3K/AKT/mTOR signaling pathway. Many cancers including HCC were often 
dependent on the PI3K/AKT/mTOR signaling pathway to promote cell growth and survival, and in 
many instances, the pathway was found to be constitutive activated in HCC tumour (Hu et al., 2003). 
Given that Hsp90 inhibitor is able to target multiple signaling pathways implicated in HCC 
pathogenesis in this study, it is thus recognised as an attractive therapeutic option in treating HCC. 
Nevertheless, as Hsp90 is at the central node of a variety of protein interaction networks, it 
is likely that targeting the chaperone would result in some undesirable consequences. Moreover, 
cancer cells are known to have the capability to respond dynamically to mitigate any detrimental 
situation that is often observed in the development of drug-resistant cancer cells. Hence, it is 
important to investigate any possible undesirable effects that could emerge from targeting Hsp90.  
Upstream regulator analysis revealed that Hsp90 inhibitor is likely to undermine many 
transcriptional regulators. However, a few of the oncogene regulators such as TRAF3, YAP1 and TAZ 
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were predicted to be activated. This could be due to the inherent protective mechanism triggered by 
the cancers cells or as a direct consequence of Hsp90 inhibition. Further study is required to validate 
this finding and subsequently, determine the biological significance of the activation of these 
regulators. In addition, in both the protein and gene expression profiles, it was found that 17-AAG 
could initiate cellular response to oxidative stress in Huh-7 cells. NRF2 response to oxidative stress 
was one the pathways enriched after the exposure to 17-AAG. Investigation of the key components 
involved in the pathway revealed that SOD2 was highly upregulated. The overexpression of SOD2 
was validated using immunoblotting. Following which, the study investigated the effects of the 
increase presence of SOD2 in Huh-7. The result revealed that pre-treatment of cells with 17-AAG 
could confer the cells with greater tolerance towards apoptosis induced via oxidative stress. Similar 
observation was seen in HepG2 cells which indicated that this phenomenon is not unique to Huh-7 
cells. In addition, this phenomenon is likely due to the inhibition of Hsp90 rather than a side effect of 
the 17-AAG due to its chemical structure as cells treated with radicicol also gave rise to a 
comparable result. The treatment with Hsp90 inhibitors had unexpectedly resulted in an increase 
tolerance of oxidative stress in cancer cells. This could allow cancer cells to develop greater 
resistance to chemotherapeutic drugs and radiotherapy that induced cancer death through oxidative 
stress.  
In conclusion, this study has uncovered molecules that are deregulated by the Hsp90 
inhibitor, 17-AAG, at both the gene and protein levels. Key molecules such as EGFR, p21/WAF1 
(CDKN1A) and Bcl-2 are likely to play a part in 17-AAG induced cell cycle arrest and apoptosis and 
could serve as a better biomarker to determine the pharmacodynamic of the drug. More 
importantly, 17-AAG was found to modulate ERK/MAPK and PI3K/AKT/mTOR signaling pathways 
that played important roles in HCC carcinogenesis. Nevertheless, the induction of various 
chaperones mediated by Hsf1, and the potential activation of oncogene such as TRAF3, YAP1 and 
TAZ could potentially interfere with the efficacy of the Hsp90 inhibitor. The study had shown in 
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principle that by targeting Hsp90, undesirable consequences, such as an increase in the ability of 
cells to withstand oxidative stress, could emerge. These issues would need to be addressed to 
provide a direction for subsequent investigation in evaluating the use of Hsp90 inhibitor for treating 
HCC.  
 







Conclusion and Future Directions 
 
  
Chapter 6 Conclusion and Future Directions 
130 
 
Chapter 6: Conclusion and Future Directions 
6.1 Introduction 
Hsp90 is an essential molecular chaperone in eukaryotes that helps in the activation of many 
proteins important for signal transduction and developmental regulation (Taipale et al., 2010). It 
emerges as a potential drug target for cancer treatment as Hsp90 was found to be involved in many 
cellular pathways which are often hijacked by cancer cells to support their pathogenesis. This project 
focused on evaluating the therapeutic potential of Hsp90 inhibitors in treating HCC. Prior to this 
study, it has been reported that derivatives of the Hsp90 inhibitor, geldanamycin, reduced cell 
growth and induced apoptosis in HCC cell lines (Breinig et al., 2009; Watanabe et al., 2009). 
Nevertheless, geldanamycin and its derivatives contain a quinone group that was predicted to cause 
off-target toxicities. Hence, it is difficult to ascertain whether the observed effects were due to the 
inhibition of Hsp90’s functionality. In addition, elucidating the mode of action of the inhibitor would 
be essential as results from the concluded clinical trials indicated that successful application of the 
Hsp90-targeted therapy would depend on gathering information with regards to cancer cell’s 
response towards Hsp90 inhibition at a global scale. Therefore, this project was initiated to 1) verify 
the Hsp90 inhibition effects on cellular processes such as cell growth, cell death and cell motility, and 
2) analyze the mechanistic action of Hsp90 inhibitor in HCC using a combined global approach of 
antibody array and gene expression microarray profiling. 
 
6.2 The Cellular Effects of Targeting Hsp90 in HCC Cell Lines 
 One of the strategies to study the biological role of a protein is the use of chemical 
compounds to inhibit the protein’s activity. However, the chemical structure of the compound could 
induce side effects that interfere with the findings of the investigation. This had compromised the 
validity of Hsp90 studies on HCC as only a single class of Hsp90 inhibitor (geldanamycin and its 
Chapter 6 Conclusion and Future Directions 
131 
 
derivatives) has been used thus far. The findings were unable to rule out the possibility that the 
quinone moiety of geldanamycin/derivatives had a role in the induced cellular effects. To overcome 
this issue, an additional Hsp90 inhibitor known as radicicol, which differs chemically from 
geldanamycin and its derivatives, was included in this study. The use of two different classes of 
Hsp90 inhibitors would further support that the observed effects were due to the abrogation of 
Hsp90 functionality as opposed to off-target effects due to the chemical backbone.  
This study had found that the Hsp90 inhibitors, 17-AAG and radicicol, independently reduced 
cellular growth and increased cell death via apoptosis in HCC cells, thus supported the importance of 
Hsp90 in these cellular processes. The results not only demonstrated the feasibility of Hsp90-
targeted therapy for HCC but also highlighted the importance of Hsp90 in the pathogenesis of HCC. 
In addition, given that metastasis is a hallmark of HCC (Hanahan and Weinberg, 2011), the study also 
examined the effect of Hsp90 inhibition on cell motility and showed through wound-healing assay 
that exposure to Hsp90 inhibitor decreases cell motility. Collectively, this study highlights the 
importance of Hsp90 in cellular processes such as cell cycle, cell death and cell motility. With the 
characterization of the cellular effects of Hsp90 inhibition, it allowed the study to subsequently 
proceed to elucidate the molecular basis of the Hsp90 inhibitor, 17-AAG, in vitro cellular effects on 
HCC. 
 
6.3 Gaining Insight Into the Mechanistic Basis of 17-AAG Induced Cellular Effects on HCC Cell Lines 
One of the key observations from the protein and gene expression profiles was the up-
regulation of various chaperone families such as Hsp70 and Hsp27 upon the treatment with 17-AAG. 
Besides chaperones, the co-chaperone Aha1 was also found to be upregulated. The common feature 
among them is the presence of HSE in their promoter region (Holmes et al., 2008). Therefore, this 
strongly suggests that Hsf1 was activated after the treatment with Hsp90 inhibitor, leading to the 
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up-regulation of various chaperones and Aha1. Given the role of Hsf1 in promoting oncogenesis, the 
induction of this transcription factor will be a concern for the future development of Hsp90-targeted 
therapies in HCC (Dai et al., 2007). Hence, an area of interest for future studies would be to 
investigate whether silencing of Hsf1 could broaden the cellular impact of Hsp90 inhibitors and 
increase cancer cells’ susceptibility towards Hsp90 inhibitors. 
So far, Hsp90 inhibitor has been demonstrated to abrogate several cellular processes in HCC 
cells although the precise mechanism linking the inhibition of Hsp90’s functionality with the resulted 
effects remains unclear. With the uncovering of molecules that were deregulated by Hsp90 inhibitor, 
17-AAG at both the gene and protein levels, it has allowed the identification of several key cellular 
molecules such as EGFR, p21/WAF1 (CDKN1A) and Bcl-2 that could have played a role in 17-AAG 
induced cell cycle arrest and apoptosis. Identification of these molecules provides an understanding 
on how Hsp90 exerts its influence on the various cellular processes in HCC cells. This could lead the 
development of improved biomarker for determining the pharmacodynamic activity of the Hsp90 
inhibitor.  
In addition, the global analysis of the genes deregulated by Hsp90 inhibitors enabled the 
study to elucidate the molecular pathways that Hsp90 would interfere in the HCC cells. ERK/MAPK 
and PI3K/AKT/mTOR signaling pathways that are important in the HCC pathogenesis were predicted 
to be altered by Hsp90 inhibitor. This information would not only shed light on the cellular roles of 
Hsp90 in regulating biochemical pathways in HCC, but also could help to predict the response of a 
patient towards Hsp90 inhibitor treatment and stratify HCC patients that are most suitable for 
Hsp90-targeted therapy. Lastly, based on the gene expression profile, several transcriptional 
regulators were predicted to be compromised by Hsp90 inhibitor. Interestingly, some of them are 
not known client proteins and therefore, could be potential novel interaction partners of Hsp90.   
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Taken together, the study had revealed the extensiveness of molecules affected by Hsp90 
inhibitor, 17-AAG, in HCC cells and consequently, its impact on various biochemical pathways that 
eventually lead to the observed cellular effects of Hsp90 inhibitor. This provides an insight into the 
molecular events that were deregulated following treatment with 17-AAG and potentially leads to 
the observed cellular effects which are crucial for exploitation of Hsp90 as a therapeutic application 
for treating HCC. 
6.4 Uncovering Potential Undesirable Effects of Hsp90 inhibitor, 17-AAG, in HCC  
Given that Hsp90 is at the central node of a variety of protein interaction networks, one 
major concern in targeting the chaperone is that it could also induce some other undesirable effects 
(Whitesell and Lindquist, 2005). Taking advantage of the global approach adopted in this study, we 
tried to uncover plausible mechanisms of any undesirable effect that may arise following the 
treatment with Hsp90 inhibitor, 17-AAG. This study found that the genes associated with NRF2 
response to oxidative stress were enriched upon exposure to 17-AAG. Closer analysis revealed that 
SOD2 was highly upregulated which would increase the tolerance of cells against oxidative stress. 
Indeed, pre-treatment of Huh-7 and HepG2 cells with 17-AAG conferred the cells with greater 
tolerance towards apoptosis induced via oxidative stress. Although further studies are required to 
directly linked SOD2 with amelioration of cancer cells to withstand oxidative stress, the 
circumstantial evidence provided the hint of undesirable effects that result from the use of Hsp90 
inhibitors. Further studies are needed to study the implication of oxidative stress induced by Hsp90 
inhibitors and also other pathways such as ATM signaling that were highlighted in this study.  
 
6.5 Conclusion 
The work presented in this study has provided insights into how the Hsp90 inhibitors would 
deregulate the genes transcript and protein expression levels in HCC cells. The alteration of the 
Chapter 6 Conclusion and Future Directions 
134 
 
transcripts and proteins reveals how various cellular processes were modulated by Hsp90 inhibitor. 
This study departs from the approach of examining only a few key oncoproteins that was often 
adopted in Hsp90 inhibitor studies. Using an approach based on the gene microarray and antibody 
array, this project had attempted to map out the global impact of Hsp90 inhibitor, 17-AAG, on HCC 
cells at both the gene and protein levels. A growing support for targeting Hsf1 in conjunction with 
Hsp90 inhibitor to maximise the clinical outcome is further reinforced by upregulation of many 
chaperones observed in this study. The identification of molecules deregulated by Hsp90, leading to 
the alteration of various molecular pathway would help in understanding the role of Hsp90 in HCC 


























Appendix B. 16 Cellular Processes that were Significantly Enriched with Genes Deregulated 





















Appendix C. 57 Ingenuity Canonical Pathways Enriched by Genes that were Differentially 




Ingenuity Canonical Pathways p-value Ratio 
LPS/IL-1 Mediated Inhibition of RXR Function 0.00000 0.16200 
PXR/RXR Activation 0.00000 0.26600 
FXR/RXR Activation 0.00000 0.22600 
Hepatic Cholestasis 0.00004 0.16300 
IL-17A Signaling in Gastric Cells 0.00018 0.32000 
TNFR2 Signaling 0.00044 0.25000 
NRF2-mediated Oxidative Stress Response 0.00046 0.13400 
Role of CHK Proteins in Cell Cycle Checkpoint Control 0.00110 0.19300 
IL-8 Signaling 0.00166 0.12500 
Xenobiotic Metabolism Signaling 0.00191 0.11600 
Signaling by Rho Family GTPases 0.00200 0.11300 
IL-17A Signaling in Fibroblasts 0.00214 0.20500 
iNOS Signaling 0.00219 0.19100 
Agranulocyte Adhesion and Diapedesis 0.00398 0.12500 
TNFR1 Signaling 0.00417 0.17600 
Aryl Hydrocarbon Receptor Signaling 0.00427 0.12800 
Antioxidant Action of Vitamin C 0.00479 0.14300 
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages 0.00562 0.11800 
Role of BRCA1 in DNA Damage Response 0.00724 0.15900 
CD27 Signaling in Lymphocytes 0.00724 0.16400 
Atherosclerosis Signaling 0.00794 0.12200 
CD40 Signaling 0.00912 0.14700 
Role of IL-17A in Psoriasis 0.00955 0.30800 
Acute Phase Response Signaling 0.01122 0.11600 
ILK Signaling 0.01259 0.11400 
Hepatic Fibrosis / Hepatic Stellate Cell Activation 0.01259 0.12100 
Leukocyte Extravasation Signaling 0.01318 0.11200 
Pancreatic Adenocarcinoma Signaling 0.01349 0.12200 
April Mediated Signaling 0.01349 0.16700 
Agrin Interactions at Neuromuscular Junction 0.01549 0.14900 
VDR/RXR Activation 0.01549 0.14100 
Granulocyte Adhesion and Diapedesis 0.01738 0.11400 
IL-12 Signaling and Production in Macrophages 0.01738 0.11700 
B Cell Activating Factor Signaling 0.01778 0.15900 
ATM Signaling 0.01862 0.14800 
LXR/RXR Activation 0.01862 0.11900 
Germ Cell-Sertoli Cell Junction Signaling 0.01862 0.11500 
Tec Kinase Signaling 0.01862 0.10300 
Complement System 0.01995 0.18200 
















Mismatch Repair in Eukaryotes 0.02089 0.20000 
Type II Diabetes Mellitus Signaling 0.02399 0.11000 
UVB-Induced MAPK Signaling 0.02455 0.14800 
Caveolar-mediated Endocytosis Signaling 0.02455 0.12300 
HMGB1 Signaling 0.02512 0.12400 
LPS-stimulated MAPK Signaling 0.02692 0.12700 
ERK/MAPK Signaling 0.02951 0.10100 
Gα12/13 Signaling 0.02951 0.11400 
PTEN Signaling 0.02951 0.10800 
Aldosterone Signaling in Epithelial Cells 0.03020 0.10900 
Glucocorticoid Receptor Signaling 0.03162 0.09390 
RANK Signaling in Osteoclasts 0.03311 0.12000 
Toll-like Receptor Signaling 0.03311 0.14000 
PI3K/AKT Signaling 0.03802 0.10400 
HIF1α Signaling 0.04074 0.11800 
IL-10 Signaling 0.04169 0.12500 
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